PCT Patents in Blood Anticlot Technology, Medications and
Medical Devices Published in 2011
Clck to enlarge and view details

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

PCT - WORLD PATENTS IN BLOOD ANTICLOT DRUGS AND DEVICES PUBLISHED IN 2011



Publication No.: WO2011005098A1  Published: 13/Jan/2011

Title: PEPTIDE LIGANDS FOR TARGETING TO THE BLOOD-BRAIN BARRIER

Applicant/Assignee: ABBOTT HEALTHCARE PRODUCTS B.V, UNIVERSITEIT LEIDEN, UNIVERSITEIT UTRECHT HOLDING B.V

Application No.: NL2010/050448   Filing Date: 12/Jul/2010

Abstract:The present invention relates to peptides comprising defined amino acid sequences, compositions comprising said peptides and a pharmaceutically acceptable substance, use of said peptides as a central nervous system targeting principle in the treatment, prophylaxis or diagnosis of a central nervous system disorders, combinations of said peptides with pharmaceutically acceptable substances, use of said combinations for the treatment, prophylaxis or diagnosis of a central nervous system disorders, a method of delivery of said peptide and of a pharmaceutically acceptable substance and a nucleic acid sequence encoding for said peptide sequence.

Priority: EP20090165239 Applic. Date: 2009-07-10

Inventor: VAN ROOY INGE [NL]; HENNINK WILHELMUS EVERHARDUS [NL]; MASTROBATTISTA ENRICO [NL]; SCHIFFELERS RAYMOND MICHEL [NL]; DINTER-HEIDORN HEIKE [DE]; BRINKHUIS RENE PASCAL [NL]; VAN HEST JAN [NL]; RUTJES FLORIS PETER JOHANNES THEODORUS [NL]


Publication No.: WO2011006084A2  Published: 13/Jan/2011

Title: VACCINES WITH ONCOFETAL ANTIGEN/ILRP-LOADED AUTOLOGOUS DENDRITIC CELLS AND USES THEREOF

Applicant/Assignee: SOUTH ALABAMA MEDICAL SCIENCE

Application No.: US2010/041556   Filing Date: 09/Jul/2010

Abstract:Disclosed are compositions containing isolated monocyte-derived mature dendritic cells loaded with OFA/iLRP, or a fragment thereof that selectively stimulates T cytotoxic lymphocytes, and a carrier, vaccine compositions containing effective dosage amounts of the dendritic cells, methods of making the vaccines, and methods of cancer treatment or therapy that entail administration of the vaccines to cancer patients.

Priority: US20090270570P Applic. Date: 2009-07-09

Inventor: ROHRER JAMES W [US]; COGGIN JOSEPH H [US]; BARSOUM ADEL L [US]


Publication No.: WO2011008939A2  Published: 20/Jan/2011

Title: POROUS-WALL HOLLOW GLASS MICROSPHERES AS CARRIERS FOR BIOMOLECULES

Applicant/Assignee: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC, SAVANNAH RIVER NUCLEAR SOLUTIONS, LLC

Application No.: US2010/042117   Filing Date: 15/Jul/2010

Abstract:The present invention includes compositions of porous-wall hollow glass microspheres and one or more biomolecules, wherein the one or more biomolecules are positioned within a void location within the hollow glass microsphere, and the use of such compositions for the diagnostic and/or therapeutic delivery of biomolecules.

Priority: US20090271005P Applic. Date: 2009-07-16

Inventor: LI SHUYI [US]; DYNAN WILLIAM S [US]; WICKS GEORGE [US]; SERKIZ STEVEN [US]


Publication No.: WO2011010966A1  Published: 27/Jan/2011

Title: PRE-NATAL MESENCHYMAL STEM CELLS

Applicant/Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR), KK WOMEN'S AND CHILDREN'S HOSPITAL, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, SINGAPORE HEALTH SERVICES PTE LTD

Application No.: SG2010/000275   Filing Date: 21/Jul/2010

Abstract:We describe an pre-natal mesenchymal stem cell obtainable from a pre-natal tissue such as a foetal tissue, a descendent of such a mesenchymal stem cell, a cell culture or a cell line comprising either. The pre-natal mesenchymal stem cell, cell culture or cell line may comprise a cell line F1Ib, F2lb, F3lb, F1ki or F3li. We further describe a conditioned medium conditioned by such a pre-natal mesenchymal stem cell, cell culture or cell line. These may comprise cardioprotective activity, and may in particular be used to treat or prevent a range of cardiac disorders of diseases.

Priority: US20090227865P Applic. Date: 2009-07-23

Inventor: LIM SAI KIANG [SG]; TAN KOK HIAN [SG]


Publication No.: WO2011011420A2  Published: 27/Jan/2011

Title: 3, 4-METHYLENEDIOXYPHENYL INHIBITORS OF GABA AMINOTRANSFERASE AND/OR GABA REUPTAKE TRANSPORTER INHIBITOR

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: US2010/042615   Filing Date: 20/Jul/2010

Abstract:The present invention relates to new 3,4-methylenedioxyphenyl inhibitors of GABA aminotransferase activity and/or GABA reuptake transporter activity, pharmaceutical compositions thereof, and methods of use thereof. Formula (I)

Priority: US20090227153P Applic. Date: 2009-07-21

Inventor: RAO TADIMETI [US]; ZHANG CHENGZHI [US]


Publication No.: WO2011011700A2  Published: 27/Jan/2011

Title: TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)

Applicant/Assignee: CURNA, INC

Application No.: US2010/043075   Filing Date: 23/Jul/2010

Abstract:The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.

Priority: US20090228392P Applic. Date: 2009-07-24; US20090259072P Applic. Date: 2009-11-06; WO2009US66445 Applic. Date: 2009-12-02; WO2010US26119 Applic. Date: 2010-03-03

Inventor: COLLARD JOSEPH [US]; KHORKOVA SHERMAN OLGA [US]


Publication No.: WO2011012989A1  Published: 03/Feb/2011

Title: S-ADENOSYLMETHIONINE FORMULATIONS WITH ENHANCED BIOAVAILABILITY

Applicant/Assignee: MSI METHYLATION SCIENCES INC

Application No.: IB2010/001877   Filing Date: 29/Jul/2010

Abstract:The invention relates to compositions and methods to enhance the absorption of S- adenosylmethionine (SAMe) and to methods of treating various disorders or diseases using non-parenteral SAMe formulations with enhanced-absorption and improved bioavailability. The enhanced bioavailability formulations may be used to treat a variety of diseases or disorders, such as for example, psychiatric disorders including, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, depressive disorders (e.g. major clinical depression) and dysthymia

as well as treating liver disorders, cancer, autoimmune disorders, inflammatory disorders, joint disorders, gastrointestinal disorders and cardiovascular disease.

Priority: US20090229194P Applic. Date: 2009-07-28

Inventor: MACDONALD I DAVID [CA]; HARRISON NANCY [CA]; TAKACS-COX ANIKO [CA]; PURAC ADMIR [CA]; BLAZEK-WELSH ALMIRA [CA]


Publication No.: WO2011017055A2  Published: 10/Feb/2011

Title: BLOOD COAGULATION PROTEIN CONJUGATES

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A

Application No.: US2010/043242   Filing Date: 26/Jul/2010

Abstract:The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.

Priority: US20090228828P Applic. Date: 2009-07-27; US20100347136P Applic. Date: 2010-05-21

Inventor: SIEKMANN JUERGEN [AT]; HAIDER STEFAN [AT]; ROTTENSTEINER HANSPETER [AT]; TURECEK PETER [AT]


Publication No.: WO2011017108A2  Published: 10/Feb/2011

Title: CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: US2010/043404   Filing Date: 27/Jul/2010

Abstract:The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20090228913P Applic. Date: 2009-07-27

Inventor: RAO TADIMETI [US]; ZHANG CHENGZHI [US]


Publication No.: WO2011017296A1  Published: 10/Feb/2011

Title: 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS

Applicant/Assignee: SCHERING CORPORATION

Application No.: US2010/044208   Filing Date: 03/Aug/2010

Abstract:The present invention relates to novel heterocyclic compounds of Formulae (I): (Chemical formula should be inserted here as it appears on abstract in paper form) Formula (I) as disclosed herein, or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.

Priority: US20090231070P Applic. Date: 2009-08-04

Inventor: CHELLIAH MARIAPPAN V [US]; CHACKALAMANNIL SAMUEL [US]; GREENLEE WILLIAM J [US]; EAGEN KEITH A [US]; GUO ZHUYAN [US]; CLASBY MARTIN C [US]; XIA YAN [US]; JAYNE CHARLES L [US]; DWYER MICHAEL [US]; KEERTIKAR KARTIK M [US]; CHAN TIN-YAU [US]; WANG LI [US]


Publication No.: WO2011019366A2  Published: 17/Feb/2011

Title: GROWTH FACTOR EXTRACTOR

Applicant/Assignee: OROGEN BIOSCIENCES, INC

Application No.: US2010/002112   Filing Date: 29/Jul/2010

Abstract:A reservoir is supported by a base in a vertical position. A reciprocating member is positioned in the reservoir forming an internal chamber. The chamber receives growth factor starting material through an inlet in the reciprocating member. After the inlet is sealed, the reciprocating member increases the volume of the chamber to apply negative pressure to the growth factor starting material within to produce activated growth factors. The activated growth factors are extracted from the chamber through an outlet in the reciprocating member. Optionally, the growth factor starting material is held in the chamber to separate into fractions.

Priority: US2009-462942 Applic. Date: 2009-08-12

Inventor: GANDY JAMES B [US]; BRANDT RYAN N [US]


Publication No.: WO2011019815A2  Published: 17/Feb/2011

Title: TREATMENT OF ADIPONECTIN (ADIPOQ) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO AN ADIPONECTIN (ADIPOQ)

Applicant/Assignee: CURNA, INC, OPKO CURNA, LLC

Application No.: US2010/045168   Filing Date: 11/Aug/2010

Abstract:The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of an Adiponectin (ADIPOQ), in particular, by targeting natural antisense polynucleotides of an Adiponectin (ADIPOQ). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Adiponectins (ADIPOQ)s.

Priority: US20090232917P Applic. Date: 2009-08-11; US20090253187P Applic. Date: 2009-10-20

Inventor: COLLARD JOSEPH [US]; KHORKOVA SHERMAN OLGA [US]


Publication No.: WO2011019956A2  Published: 17/Feb/2011

Title: PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: BIOVAIL LABORATORIES INTERNATIONAL (BARBADOS) S.R.L

Application No.: US2010/045375   Filing Date: 12/Aug/2010

Abstract:The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent

and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.

Priority: US2009-540144 Applic. Date: 2009-08-12; WO2009GB51013 Applic. Date: 2009-08-12

Inventor: DUFFIELD ANDREW JOHN [GB]; JACKSON GRAHAM [BB]; FRISBEE STEVEN E [US]; ERADIRI OKPONANABOFA [US]; LAI JOHN CK [US]


Publication No.: WO2011020866A2  Published: 24/Feb/2011

Title: ALBUMIN FUSED COAGULATION FACTORS FOR NON-INTRAVENOUS ADMINISTRATION IN THE THERAPY AND PROPHYLACTIC TREATMENT OF BLEEDING DISORDERS

Applicant/Assignee: CSL BEHRING GMBH

Application No.: EP2010/062069   Filing Date: 18/Aug/2010

Abstract:The present invention relates to pharmaceutical preparations comprising albumin- fused coagulation factors for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders and to a method for increasing the in- vivo recovery after non-intravenous administration of a coagulation factor by fusing it to albumin.

Priority: EP20090010699 Applic. Date: 2009-08-20; US20090237006P Applic. Date: 2009-08-26

Inventor: KRONTHALER ULRICH [DE]


Publication No.: WO2011022427A1  Published: 24/Feb/2011

Title: APTAMERS TO TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE AS BLEEDING DISORDER THERAPEUTICS

Applicant/Assignee: ARCHEMIX CORP

Application No.: US2010/045797   Filing Date: 17/Aug/2010

Abstract:The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.

Priority: US20100366362P Applic. Date: 2010-07-21; US20100353374P Applic. Date: 2010-06-10; US20090234939P Applic. Date: 2009-08-18; US20100367766P Applic. Date: 2010-07-26

Inventor: SCHAUB ROBERT G [US]; MCGINNESS KATHLEEN [US]; NELSON JENNIFER [US]; GENGA RYAN [US]; WATERS EMILY [US]; KURZ JEFFREY C [US]; DIENER JOHN L [US]


Publication No.: WO2011023653A1  Published: 03/Mar/2011

Title: EMERGENCY INTERVENTIONS OF ACTIVE CHARCOAL WITH DABIGATRAN ETEXILATE OVERDOSING

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: EP2010/062229   Filing Date: 23/Aug/2010

Abstract:The invention relates to a method for treating an overdosing with active substance dabigatran etexilate of formula I optionally in the form of the pharmaceutically acceptable salts thereof, comprising the administration of an effective amount of charcoal.

Priority: US20090236321P Applic. Date: 2009-08-24

Inventor: VAN RYN JOANNE [DE]; CLEMENS ANDREAS [DE]


Publication No.: WO2011024154A1  Published: 03/Mar/2011

Title: USE OF IRBESARTAN FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION OF HOSPITALIZATION FOR HEART FAILURE.

Applicant/Assignee: SANOFI-AVENTIS

Application No.: IB2010/053904   Filing Date: 31/Aug/2010

Abstract:Use of irbesartan or one of its pharmaceutically acceptable salts for the preparation of a medicament for the prevention of hospitalization for heart failure.

Priority: FR20090004132 Applic. Date: 2009-08-31

Inventor: GAUDIN CHRISTOPHE [FR]; MARCHESE CATHERINE [FR]


Publication No.: WO2011025565A1  Published: 03/Mar/2011

Title: MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS

Applicant/Assignee: MOCHIDA PHARMACEUTICAL CO., LTD, SCHERING CORPORATION

Application No.: US2010/036853   Filing Date: 01/Jun/2010

Abstract:The present invention provides compounds having the formula (I) or a pharmaceutically acceptable salt or a solvate thereof, pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.

Priority: US20090238455P Applic. Date: 2009-08-31; WO2009US66548 Applic. Date: 2009-12-03

Inventor: NISHIDA HIDEMITSU [JP]; SAITOH FUMIHIKO [JP]; HIRABAYASHI TOMOKAZU [JP]; CHACKALAMANNIL SAMUEL [US]; CHAN TIN-YAU [US]; CHELLIAH MARIAPPAN V [US]; CLASBY MARTIN C [US]; DWYER MICHAEL P [US]; GREENLEE WILLIAM J [US]; XIA YAN [US]; NEELAMKAVIL SANTHOSH [US]; SHAH UNMESH G [US]


Publication No.: WO2011025978A2  Published: 03/Mar/2011

Title: METHODS OF TREATMENT USING ANTI-OXIDIZED LDL ANTIBODIES

Applicant/Assignee:

Application No.: US2010/047030   Filing Date: 27/Aug/2010

Abstract:The present invention relates to methods and compositions for increasing insulin sensitivity comprising the administration of anti-oxidized LDL antibodies.

Priority: US20090238114P Applic. Date: 2009-08-28

Inventor: BUNTING STUART [US]; BULLENS SHERRON [US]; CARLSSON ROLAND [SE]; FRENDEUS BJOERN [SE]; GLAZER STEVEN [DK]; GROVE KEVIN [US]; VAN BRUGGEN NICK [US]


Publication No.: WO2011027175A1  Published: 10/Mar/2011

Title: ANTITHROMBOTIC COMPOUNDS

Applicant/Assignee: KING'S COLLEGE LONDON, IMPERIAL INNOVATIONS LIMITED

Application No.: GB2010/051478   Filing Date: 06/Sep/2010

Abstract:A soluble compound for preventing or reducing blood coagulation comprising an antithrombotic agent and a membrane binding element, wherein the antithrombotic agent has a weight of less than about 5,000 daltons. Also disclosed is a soluble compound for preventing or reducing blood coagulation comprising an anticoagulant joined to a membrane binding element via a joining element, wherein the joining element between the anticoagulant and the membrane binding element is less than about 10,000 daltons in weight. These compounds can be used in therapy and, in particular, in preventing or reducing blood coagulation. As a result, a method of treatment is provided comprising administering an effective amount of the compounds to a subject to prevent or reduce blood coagulation as well as a method of perfusing an organ, tissue or cell comprising contacting the compounds with the organ, tissue or cell to prevent or reduce blood coagulation. Also disclosed is an organ, tissue or cell which has been perfused with the compounds.

Priority: GB20090015519 Applic. Date: 2009-09-04

Inventor: SMITH RICHARD ANTHONY GODWIN [GB]; SACKS STEVEN HOWARD [GB]; DORLING ANTHONY [GB]


Publication No.: WO2011028733A1  Published: 10/Mar/2011

Title: COMPOSITIONS AND MINIMALLY INVASIVE METHODS FOR TREATING CANCER

Applicant/Assignee:

Application No.: US2010/047393   Filing Date: 31/Aug/2010

Abstract:Methods are described for using compositions containing platelet-rich plasma for the treatment of a cancer in a variety of tissues. Particularly, treatment of brain cancer with platelet releasate is described.

Priority: US20090239892P Applic. Date: 2009-09-04

Inventor: MISHRA ALLAN [US]


Publication No.: WO2011029208A1  Published: 17/Mar/2011

Title: DEVICE TO BE IMPLANTED IN A HUMAN OR ANIMAL BODY FOR MATERIAL OR SIGNAL DELIVERY OR ACQUISITION WITHIN THE BODY

Applicant/Assignee: WOODWELDING AG

Application No.: CH2010/000217   Filing Date: 07/Sep/2010

Abstract:For fixedly implanting a device for material or signal delivery or acquisition or a part of such a device in a human or animal body, an opening is provided in hard tissue of the body, the opening reaching through a hard tissue layer, e.g. through a cortical bone layer (2) into cancellous bone (1 ) underneath. The device comprises a plug portion (P) and/or a cover portion (C) which comprises a ring (7) of a material having thermoplastic properties extending around the plug portion (P) or on a tissue facing surface of the cover portion (C). The opening (9) provided in the hard tissue has a cross section at least in the area of its mouth that is adapted to the plug or cover portion such that the plug portion (P) can be introduced through the mouth of the opening (9) or the cover portion (C) can be positioned over the mouth of the opening (9) such that the ring (7) extends around the opening, along its wall and/or on the hard tissue surface around its mouth. For implantation the device is positioned with the plug portion (P) in the mouth of the opening and/or the cover portion (C) over the opening, the material having thermoplastic properties is then liquefied e.g. through application of vibrational energy and is made to get into contact with the wall of the opening and/or with the hard tissue surface all around the opening. On resolidification the material having thermoplastic properties constitutes a sealing ring (11) between device and hard tissue. The device is e.g. equipped as drug delivery device for intra-osseous or intra-articular drug delivery and is implanted through the cortical bone layer in the vicinity of a Joint. The sealing ring (11) fully prevents migration of the drug or other undesired substances along the device surface through the cortical bone layer.

Priority: US20090241184P Applic. Date: 2009-09-10

Inventor: MAYER JOERG [CH]; FROESCH BARBARA [CH]; LEHMANN MARIO [CH]; LANGHOFF JENS [CH]; KNECHT THOMAS [CH]


Publication No.: WO2011029903A1  Published: 17/Mar/2011

Title: METHOD FOR THE PREPARATION OF MICRO-RNA AND ITS THERAPEUTIC APPLICATION

Applicant/Assignee:

Application No.: EP2010/063313   Filing Date: 10/Sep/2010

Abstract:The present invention relates to compositions comprising a therapeutically effective amount of miRNAs, their use for the treatment of medical conditions benefiting from being treated with these compositions, as well as methods for the preparation of compositions comprising miRNAs.

Priority: EP20090169937 Applic. Date: 2009-09-10

Inventor: VELIN FLEMMING [DK]; LINDENBERG SVEND [DK]


Publication No.: WO2011031524A2  Published: 17/Mar/2011

Title: METHODS AND COMPOSITIONS FOR DELIVERING INTERLEUKIN-1 RECEPTOR ANTAGONIST

Applicant/Assignee: BIOMET BIOLOGICS, LLC

Application No.: US2010/046821   Filing Date: 26/Aug/2010

Abstract:Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating adipose tissue and/or adipocytes with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.

Priority: US2009-549015 Applic. Date: 2009-08-27

Inventor: HIGGINS JOEL C [US]; WOODELL-MAY JENNIFER E [US]; HOEPPNER JACY [US]


Publication No.: WO2011031525A1  Published: 17/Mar/2011

Title: OSTEOLYSIS TREATMENT

Applicant/Assignee: BIOMET BIOLOGICS, LLC

Application No.: US2010/046826   Filing Date: 26/Aug/2010

Abstract:Methods and treatments for osteolysis employing interleukin-1 receptor antagonist (IL-1ra). Activating production of interleukin-1 receptor antagonist includes incubating adipose tissue, adipocytes, whole blood, platelet rich plasma, and/or isolated white blood cells with polyacrylamide beads to produce a solution rich in interleukin-1 receptor antagonist. Activating the production of interleukin-1 receptor antagonist includes using an implantable device loaded with adipose tissue, adipocytes, whole blood, platelet rich plasma, and/or isolated white blood cells. Methods for treating osteolysis at the site of an artificial joint in a patient include administering and/or inserting the solution rich in interleukin-1 receptor antagonist and/or the implantable device, respectively.

Priority: US2009-549116 Applic. Date: 2009-08-27

Inventor: HOEPPNER JACY [US]


Publication No.: WO2011031553A2  Published: 17/Mar/2011

Title: IMPLANTABLE DEVICE FOR PRODUCTION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST

Applicant/Assignee: BIOMET BIOLOGICS, LLC

Application No.: US2010/046994   Filing Date: 27/Aug/2010

Abstract:Treatments and devices for generating and using interleukin-1 receptor antagonist (IL-1ra). An implantable device is loaded with adipose tissue and/or white blood cells and inserted into an inflammation site in a patient to produce interleukin-1 receptor antagonist in vivo. The implantable device has an enclosed or substantially enclosed body that defines an internal space. At least a portion of the body comprises a first bioresorbable material and a second bioresorbable material is within the internal space along with one or more voids. The second bioresorbable material includes an activation surface to activate adipose tissue and/or white blood cells loaded into the device to produce IL-1ra.

Priority: US20090237484P Applic. Date: 2009-08-27

Inventor: HIGGINS JOEL C [US]; MCKALE JAMES [US]; WOODELL-MAY JENNIFER E [US]


Publication No.: WO2011031642A2  Published: 17/Mar/2011

Title: TISSUE ENGINEERED MENISCUS REPAIR COMPOSITION

Applicant/Assignee: MUSCULOSKELETAL TRANSPLANT FOUNDATION INC

Application No.: US2010/047881   Filing Date: 03/Sep/2010

Abstract:A meniscus repair composition for application to a meniscus injury to promote growth of new tissue at the meniscus injury site is provided. The composition comprises: from about 10 to about 50 percent by weight of allograft meniscus particles having an average particle size of from about 10 [mu]m to about 500 [mu]m

and a carrier comprising a solid fibrin web matrix. When introduced to a defect site in a meniscus, the composition is non-adhering to the defect site. A method for repairing a meniscus injury comprises administering a meniscus repair composition to the injury site.

Priority: US20090240395P Applic. Date: 2009-09-08

Inventor: SEMLER ERIC J [US]; GERTZMAN ARTHUR A [US]; HUANG YEN-CHEN [US]; YANNARIELLO-BROWN JUDITH [US]; TRUNCALE KATHERINE GOMES [US]


Publication No.: WO2011034775A2  Published: 24/Mar/2011

Title: METHODS FOR TREATING BRAIN TUMORS

Applicant/Assignee: KOMINOX USA, INC, KOMINOX, INC

Application No.: US2010/048314   Filing Date: 09/Sep/2010

Abstract:The present invention relates to methods treating brain tumors comprising administering a subject in need thereof a therapeutically effective amount of sodium meta arsenite, alone or in combination with another anti-brain tumor medicament.

Priority: US20090243648P Applic. Date: 2009-09-18

Inventor: JO YONG JOON [US]; YANG YONG-JIN [KR]


Publication No.: WO2011036442A2  Published: 31/Mar/2011

Title: POLYPEPTIDES AND USES THEREOF

Applicant/Assignee: XIMMUNE AB

Application No.: GB2010/001778   Filing Date: 22/Sep/2010

Abstract:The present invention provides polypeptides comprising or consisting of an amino acid sequence from thrombin, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of any one of SEQ ID NOs: 1 to 7, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti-inflammatory activity, together with isolated nucleic acid molecules, vectors and host cells for making the same.

Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.

Priority: GB20090016576 Applic. Date: 2009-09-22

Inventor: KALLE MARTINA [DE]; KASETTY GOPINATH [SE]; MALMSTEN NILS MARTIN [SE]; PAPAREDDY PRAVEEN [SE]; SCHMIDTCHEN ARTUR [SE]; WALSE BJOEM ULRIK [SE]


Publication No.: WO2011036443A2  Published: 31/Mar/2011

Title: POLYPEPTIDES AND USES THEREOF

Applicant/Assignee: XIMMUNE AB

Application No.: GB2010/001779   Filing Date: 22/Sep/2010

Abstract:The present invention provides polypeptides comprising or consisting of an amino acid sequence from the C-terminal region of an S1 serine peptidase, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the bllod. Related aspects of the invention provide isolated polypeptides comprising or consisting of any one of amino acid sequences SEQ ID NO: 1 or 113, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti-inflammatory and/or anti-microbial and/or anti-coagulant activity, together with isolated nucleic acid molecules, vectors and host cells for making the same.

Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.

Priority: GB20090016576 Applic. Date: 2009-09-22

Inventor: KASETTY GOPINATH [SE]; MALMSTEN NILS MARTIN [SE]; PAPAREDDY PRAVEEN [SE]; SCHMIDTCHEN ARTUR [SE]; WALSE BJOEM ULRIK [SE]


Publication No.: WO2011036444A1  Published: 31/Mar/2011

Title: HEPARIN COFACTOR II FRAGMENTS WITH ANTI-INFLAMMATORY AND ANTI-COAGULANT ACTIVITY

Applicant/Assignee: XIMMUNE AB

Application No.: GB2010/001780   Filing Date: 21/Sep/2010

Abstract:The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from a naturally occurring protein which modulates blood coagulation, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of SEQ ID NOS: 1 to 3, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti- inflammatory activity, together with isolated nucleic acid molecules, vectors and host cells for making the same.

Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.

Priority: GB20090016578 Applic. Date: 2009-09-22

Inventor: KALLE MARTINA [SE]; KASETTY GOPINATH [SE]; MALMSTEN NILS MARTIN [SE]; PAPAREDDY PRAVEEN [SE]; SCHMIDTCHEN ARTUR [SE]; WALSE BJOEM ULRIK [SE]


Publication No.: WO2011036445A2  Published: 31/Mar/2011

Title: POLYPEPTIDES AND USES THEREOF

Applicant/Assignee: XIMMUNE AB

Application No.: GB2010/001781   Filing Date: 22/Sep/2010

Abstract:The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from a naturally occurring protein which modulates blood coagulation, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of SEQ ID NOs: 1 to 11, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, which exhibit an anti- inflammatory and/or anti-coagulant activity, together with isolated nucleic acid molecules, vectors and host cells for making the same.

Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.

Priority: GB20090016578 Applic. Date: 2009-09-22

Inventor: KALLE MARTINA [SE]; MALMSTEN NILS MARTIN [SE]; PAPAREDDY PRAVEEN [SE]; RYDENGAARD VICTORIA [SE]; SCHMIDTCHEN ARTUR [SE]; WALSE BJOERN ULRIK [SE]


Publication No.: WO2011037912A1  Published: 31/Mar/2011

Title: COMPOSITIONS AND METHODS FOR INDUCING OR ENHANCING CONNECTIVE TISSUE REPAIR

Applicant/Assignee: GLENPHARMA AB

Application No.: US2010/049640   Filing Date: 21/Sep/2010

Abstract:A composition capable of attenuating platelet hyperactivation and associated methods for administering the same to a subject, the composition comprising an aqueous solution containing from about 0.1% to about 7.0% by weight of a glycosaminoglycan and from about 1.0% to about 32% by weight of a neutral polysaccharide.

Priority: US20090272427P Applic. Date: 2009-09-23

Inventor: BUCKLEY PETER BYRON [SE]; MESSMER KONRAD [DE]; PHILLIPS MARK WILLIAM [US]


Publication No.: WO2011038047A1  Published: 31/Mar/2011

Title: METHODS OF TREATMENT WITH A LOW MOLECULAR WEIGHT HEPARIN COMPOSITION

Applicant/Assignee: MOMENTA PHARMACEUTICALS, INC

Application No.: US2010/049890   Filing Date: 22/Sep/2010

Abstract:Methods of identifying and selecting subjects for treatment with a low molecular weight heparin (LMWH) composition are provided. Methods of treatment with the LMWH compositions are also provided.

Priority: US20090245089P Applic. Date: 2009-09-23

Inventor: FIER IAN [US]; ROACH JAMES [US]; RAO SUNIL V [US]; BECKER RICHARD CLINTON [US]


Publication No.: WO2011038298A1  Published: 31/Mar/2011

Title: USE OF DIPYRIDAMOLE IN CHRONIC ISCHEMIA

Applicant/Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

Application No.: US2010/050305   Filing Date: 24/Sep/2010

Abstract:The present invention relates generally to the healing of the human body using dipyridamole. Further, the present invention relates to compounds for healing the organs via angiogenesis, arteriogenesis, and normalization of vasculature function utilizing dipyridamole. The present invention is directed to a composition and method of utilizing dipyridamole for therapeutic angiogenesis, arteriogenesis, and normalization of vascular function to treat a number of diseases, injuries, and other ailments such as peripheral artery disease, ischemic tissue damage, inflammatory bowel disease and others by facilitating tissue repair. Further the present invention provides enhanced organ function following transplantation of various organs such as the heart, liver, pancreas, and the bowel.

Priority: US20090277481P Applic. Date: 2009-09-25

Inventor: KEVIL CHRISTOPHER G [US]


Publication No.: WO2011040969A1  Published: 07/Apr/2011

Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OTHER RELATED DISEASES

Applicant/Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL

Application No.: US2010/002655   Filing Date: 30/Sep/2010

Abstract:The present invention provides compositions and methods for the treatment of atherosclerosis and other related diseases. In some embodiments, a method comprises providing a composition and forming a coating of the composition on at least a portion of the interior and/or exterior surface of a tissue lumen or other body surface. The composition may remain associated with the tissue lumen or other body surface even in the presence of a strong flow of a fluid (e.g., blood flow in a blood vessel). The composition may associate with the tissue lumen via a plurality of covalent bonds. In some cases, the compositions may comprise at least one additive, for example, a therapeutically active agent or an imaging agent.

Priority: US20090247423P Applic. Date: 2009-09-30

Inventor: KASTRUP CHRISTIAN [US]; ANDERSON DANIEL GRIFFITH [US]; LANGER ROBERT S [US]; LEE HAESHIN [KR]; NAHRENDORF MATTHIAS [US]; WEISSLEDER RALPH [US]; FIGUEIREDO JOSE LUIZ [US]


Publication No.: WO2011044329A2  Published: 14/Apr/2011

Title: DEVICES, SYSTEMS AND METHODS FOR CELL MODIFICATION

Applicant/Assignee: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Application No.: US2010/051772   Filing Date: 07/Oct/2010

Abstract:A method of modifying cells includes removing fluid including cells from a patient, contacting the removed fluid from the patient with at least one surface upon which at least one agent to interact at least one cell receptor is immobilized to modify cells in the fluid, and returning the fluid to the patient. The agent can, for example, be immobilized via covalent bonding or ionic bonding to the at least one surface. The fluid can, for example, be blood or a blood fraction. The agent can, for example, be an agonist, an antagonist or an inverse agonist.

Priority: US20090249318P Applic. Date: 2009-10-07

Inventor: FEDERSPIEL WILLIAM J [US]; KELLUM JOHN ALSTON [US]; SINGBARTL KAI [US]


Publication No.: WO2011044377A2  Published: 14/Apr/2011

Title: CHELATOR-TARGETING LIGAND CONJUGATES FOR CARDIOVASCULAR IMAGING

Applicant/Assignee: CELL POINT, LLC

Application No.: US2010/051847   Filing Date: 07/Oct/2010

Abstract:Disclosed are methods of imaging a site in a heart of a subject to detect cardiovascular disease that involve stressing a subject, administering to the stressed subject an effective amount of a radionuclide-labeled chelator-glucose analog conjugate, and imaging the heart of the subject by detecting a signal generated by the conjugate in the heart of the subject. Also disclosed are methods of imaging a peripheral blood vessel in a subject by using a detectable amount of a radionuclide-labeled chelator-glucose analog conjugate.

Also disclosed are methods of distinguishing a false positive nuclear cardiology scan from a true positive nuclear cardiology scan, methods of diagnosing congestive heart failure or cardiac ischemia that involve imaging a subject that has been administered a radionuclide-labeled chelator-glucose analog conjugate, and methods to distinguish viable from nonviable myocardium.

Priority: US20090250331P Applic. Date: 2009-10-09

Inventor: ROLLO F DAVID [US]; BRYANT JERRY [US]


Publication No.: WO2011047266A1  Published: 21/Apr/2011

Title: IL-1 BINDING PROTEINS

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: US2010/052849   Filing Date: 15/Oct/2010

Abstract:The present invention describes IL-1ss binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1ss. Binding proteins of the invention have high affinity for IL-1ss and neutralize IL-1ss activity. A binding protein of the invention can be a full-length antibody or an IL-1ss -binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1ss binding proteins of the invention are useful for detecting IL-1ss and for inhibiting IL-1ss activity, including in a human subject suffering from a disease or disorder in which IL-1ss activity is detrimental.

Priority: US20090251856P Applic. Date: 2009-10-15

Inventor: HSIEH CHUNG-MING [US]; WU CHENGBIN [US]; MILLER RENEE [US]; AMBROSI DOMINIC J [US]


Publication No.: WO2011047473A1  Published: 28/Apr/2011

Title: HERBAL COMPOSITION COMPRISING GINGER AND GOLDENROD FOR THE TREATMENT OF COLD AND FLU

Applicant/Assignee: BIOPHARMACOPAE INC

Application No.: CA2010/001657   Filing Date: 22/Oct/2010

Abstract:Described herein is a composition comprising a combination of ginger and goldenrod for the prevention and/or treatment of cold and/or flu infection. Also described is a method of treating or preventing a cold and/or flu infection in a subject in need thereof comprising administering to the subject an effective amount of a composition comprising a combination of ginger and goldenrod.

Priority: US20090254031P Applic. Date: 2009-10-22; US20100308052P Applic. Date: 2010-02-25

Inventor: CYR BENOIT [CA]; GUAY JOHANE [CA]; PAGE BRIGITTE [CA]; GENDRON NATHALIE [CA]


Publication No.: WO2011048350A1  Published: 28/Apr/2011

Title: TREATMENT USING REPROGRAMMED MATURE ADULT CELLS

Applicant/Assignee: TRISTEM TRADING (CYPRUS) LIMITED

Application No.: GB2009/051396   Filing Date: 19/Oct/2009

Abstract:A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In certain embodiments, the method comprises obtaining committed cells from the patient, transdifferentiating the committed cells to obtain transdifferentiated target cells, and administering the transdifferentiated target cells to the patient. The retrodifferentiated or transdifferentiated target cells repair or replenish tissue or cells in the patient.

Priority:

Inventor: ABULJADAYEL ILHAM MOHAMMED SALEH SAEED [GB]


Publication No.: WO2011053730A1  Published: 05/May/2011

Title: METHOD FOR MAKING TARGETED THERAPEUTIC AGENTS DIRECTED TO SOLUBLE TARGETS

Applicant/Assignee: PROTEONOVA

Application No.: US2010/054556   Filing Date: 28/Oct/2010

Abstract:Provided herein are methods for making targeted therapeutics that target soluble agents such as toxins, venoms, and factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments the targeted therapeutics comprise a portion that interacts with a soluble agent of interest and a second portion that interacts with a subject's immune system, which enables treatment of a patient for exposure to the soluble agent.

Priority: US20090256823P Applic. Date: 2009-10-30

Inventor: WILLIAMS RICHARD B [US]; GUERRERO ROBERT [US]


Publication No.: WO2011054759A1  Published: 12/May/2011

Title: NEW THERAPEUTIC APPROACHES FOR TREATING ALZHEIMER DISEASE

Applicant/Assignee: PHARNEXT

Application No.: EP2010/066510   Filing Date: 29/Oct/2010

Abstract:The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease and related disorders. In particular, the invention concerns compounds which, alone or in combination(s),can effectively modulate synapse function and/or angiogenesis and/or cell stress response. The invention also relates to methods of producing a drug or a drug combination for treating Alzheimer's disease and to methods of treating Alzheimer's disease or a related disorder.

Priority: EP20090306048 Applic. Date: 2009-11-03

Inventor: COHEN DANIEL [FR]; CHUMAKOV ILYA [FR]; NABIROCHKIN SERGUEI [FR]


Publication No.: WO2011056511A2  Published: 12/May/2011

Title: 4,6-DIAMINOPYRIMIDINE STIMULATORS OF SOLUBLE GUANYLATE CYCLASE

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: US2010/053969   Filing Date: 25/Oct/2010

Abstract:The present invention relates to new 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20090254812P Applic. Date: 2009-10-26

Inventor: RAO TADIMETI [US]; ZHANG CHENGZHI [US]


Publication No.: WO2011057129A2  Published: 12/May/2011

Title: COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH

Applicant/Assignee: ALLERGAN, INC

Application No.: US2010/055712   Filing Date: 05/Nov/2010

Abstract:Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula (I) wherein the dashed bonds represent the presence or absence of a double bond which can be in the cis or trans configuration and A, B, Z, X, R1 and R2 are as defined in the specification and a penetration enhancer. Such compositions are used in stimulating hair growth of human or non-human animals.

Priority: US20090259368P Applic. Date: 2009-11-09

Inventor: TROGDEN JOHN T [US]; SALAMEH ADNAN [US]; PUJARA CHETAN P [US]


Publication No.: WO2011057131A1  Published: 12/May/2011

Title: POLYSACCHARIDE BASED HYDROGELS

Applicant/Assignee: SPOTLIGHT TECHNOLOGY PARTNERS LLC

Application No.: US2010/055714   Filing Date: 05/Nov/2010

Abstract:Polysaccharide based hydrogel compositions and methods of making and using the same are provided. The subject polysaccharide based hydrogel compositions are prepared by combining a polysaccharide component with a hydrophilic polymer and a cross-linking agent. Also provided are kits and systems for use in preparing the subject compositions.

Priority: US20090259564P Applic. Date: 2009-11-09

Inventor: GONG GLEN [US]; PAI SURESH SUBRAYA [US]; SERSHEN SCOTT ROBERT [US]


Publication No.: WO2011060363A2  Published: 19/May/2011

Title: CYCLOHEXYL UREA MODULATORS OF D2 RECEPTORS AND/OR D3 RECEPTORS

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: US2010/056714   Filing Date: 15/Nov/2010

Abstract:The present invention relates to new cyclohexyl urea modulators of D2 receptors and/or modulators of D3 receptors, pharmaceutical compositions thereof, and methods of use thereof.

Priority: US20090261511P Applic. Date: 2009-11-16

Inventor: NEWBOLD RONALD [US]; ZHANG CHENGZHI [US]


Publication No.: WO2011063048A2  Published: 26/May/2011

Title: URINARY TRIAOSYLCERAMIDE (GB3) AS A MARKER OF CARDIAC DISEASE

Applicant/Assignee: BAYLOR RESEARCH INSTITUTE

Application No.: US2010/057112   Filing Date: 17/Nov/2010

Abstract:The present invention describes a method for determination of urinary globotriaosylceramide (Gb3) levels in non-Fabry disease cardiac patients. Determination of Gb3 levels provides a screening method for determining cardiac risk and may offer an alternative therapeutic option for cardiac disease management or cardiac disease risk mitigation by lowering Gb3 levels by the use of pharmacological chaperones or other agents.

Priority: US20090261831P Applic. Date: 2009-11-17

Inventor: SCHIFFMANN RAPHAEL [US]; MOCHEL FANNY [US]; SWEETMAN LAWRENCE [US]; FORNI SABRINA [US]


Publication No.: WO2011068897A1  Published: 09/Jun/2011

Title: METHOD FOR REMOVING CYTOKINES FROM BLOOD WITH SURFACE IMMOBILIZED POLYSACCHARIDES

Applicant/Assignee: EXTHERA MEDICAL, LLC

Application No.: US2010/058596   Filing Date: 01/Dec/2010

Abstract:The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

Priority: US20090265675P Applic. Date: 2009-12-01

Inventor: WARD ROBERT S [US]; MCCREA KEITH R [US]; LARM OLLE [SE]; ADOLFSSON LARS [SE]


Publication No.: WO2011069082A2  Published: 09/Jun/2011

Title: RED BLOOD CELL-MIMETIC PARTICLES AND METHODS FOR MAKING AND USE THEREOF

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: US2010/058921   Filing Date: 03/Dec/2010

Abstract:The present technology provides synthesized particles that mimic key structural and functional features of red blood cells. Such RBC-mimicking particles possess the ability to carry oxygen (and carbon dioxide) and flow through capillaries smaller than their own diameter. Further, such particles can also deliver drugs and imaging agents. These particles provide a new paradigm for the design of drug delivery and imaging carriers since they combine the functionality of natural RBCs with the broad applicability and versatility of synthetic drug delivery particles. Further, such particles can be used for detoxification and other biomedical applications.

Priority: US20090266927P Applic. Date: 2009-12-04

Inventor: LAHANN JOERG [US]; MITRAGOTRI SAMIR [US]; BHASKAR SRIJANANI [US]; DOSHI NISHIT [US]; ZAHR ALISAR S [US]


Publication No.: WO2011069121A1  Published: 09/Jun/2011

Title: MESENCHYMAL STEM CELLS (MSCS) ISOLATED FROM MOBILIZED PERIPHERAL BLOOD

Applicant/Assignee: NEOSTEM, INC

Application No.: US2010/058980   Filing Date: 03/Dec/2010

Abstract:The present invention generally relates to methods of obtaining peripheral blood-derived MSCs (PB- derived MSCs) and bone-marrow derived MSC (BM-derived MSCs) from a peripheral blood sample obtained from a human subject. In particular, the present invention relates to the surprising discovery that the mobilization of MSC into the peripheral blood is temporally regulated and that the number of circulating MSCs in human peripheral blood peaks after at least 2 days post administration of a mobilizing agent, such as G-CSF or GM-CSF to a human subject. Accordingly, in some embodiments, the present invention relates to methods of obtaining PB-derived and BM-derived MSC from peripheral blood from a human subject in vivo and ex vivo using mobilizing agents, such as G-CSF or GM-CSF, where administration of G-CSF and/or GM-CSF are optimized to mobilize MSCs and enrich the number of MSCs in the peripheral blood as apposed to other stem cell populations, such as HSCs.

Priority: US20090266825P Applic. Date: 2009-12-04; TW20100104520 Applic. Date: 2010-02-10

Inventor: MARASCO WAYNE [US]; MEDICETTY SATISH [US]; JIANG YAJUAN [US]


Publication No.: WO2011072012A2  Published: 16/Jun/2011

Title: IMPROVED METHODS AND COMPOSITIONS FOR VEIN HARVEST AND AUTOGRAFTING

Applicant/Assignee: VANDERBILT UNIVERSITY

Application No.: US2010/059459   Filing Date: 08/Dec/2010

Abstract:The leading cause of graft failure is the subsequent development of intimal hyperplasia, which represents a response to injury that is thought to involve smooth muscle proliferation, migration, phenotypic modulation, and extracellular matrix (ECM) deposition. Surgical techniques typically employed for vein harvest - stretching the vein, placing the vein in low pH, solutions, and the use of toxic surgical skin markers - are shown here to cause injury. The invention therefore provides for non-toxic surgical markers than also protect against stretch-induced loss of functional viability, along with other additives. Devices and compositions for reducing physical stress or protecting from the effects flowing therefrom, also are provided.

Priority: US20090267640P Applic. Date: 2009-12-08

Inventor: BROPHY COLLEEN [US]; KOMALAVILAS PADMINI [US]; CHEUNG-FLYNN JOYCE [US]; HOCKING KYLE [US]; EAGLE SUSAN [US]


Publication No.: WO2011072398A1  Published: 23/Jun/2011

Title: LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS

Applicant/Assignee: INTERFACE BIOLOGICS, INC

Application No.: CA2010/002036   Filing Date: 20/Dec/2010

Abstract:The invention relates to oligofluorinated coatings and their use in drag delivery The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface.

Priority: US20090287862P Applic. Date: 2009-12-18

Inventor: ESFAND ROSEITA [CA]; SANTERRE J PAUL [CA]; TJAHYADI SYLVIA [CA]; ILAGAN BERNADETTE [CA]


Publication No.: WO2011075391A1  Published: 23/Jun/2011

Title: FORMULATIONS OF ACADESINE

Applicant/Assignee: SCHERING CORPORATION

Application No.: US2010/059701   Filing Date: 09/Dec/2010

Abstract:This invention provides a buffered solution comprising acadesine, as well as compositions, formulations and kits containing said solution. The solution, compositions, formulation, and kits can be used to prevent morbidity/mortality in a patient or to treat an ischaemic condition, a condition regulated by adenosine, or a condition associated with reduced blood flow to a tissue in a patient.

Priority: US20090286564P Applic. Date: 2009-12-15

Inventor: ANTOCHSHUK VALENTYN [US]; BHALLA AMARDEEP SINGH BHUPENDER [US]; SHAMEEM MOHAMMED [US]


Publication No.: WO2011075596A1  Published: 23/Jun/2011

Title: CRYSTALLINE FORMS OF CERTAIN 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Applicant/Assignee: ARENA PHARMACEUTICALS, INC

Application No.: US2010/060848   Filing Date: 16/Dec/2010

Abstract:Provided are certain solvates of 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions comprising such solvates and methods for their use.

Priority: US20090288130P Applic. Date: 2009-12-18

Inventor: STIRN SCOTT [US]; LALLY EDWARD A [US]


Publication No.: WO2011075623A1  Published: 23/Jun/2011

Title: ONE - PHASE GEL COMPOS ITION COMPRI S ING PHOS PHOLI PIDS

Applicant/Assignee: LATITUDE PHARMACEUTICALS, INC

Application No.: US2010/060964   Filing Date: 17/Dec/2010

Abstract:The present invention is directed to compositions and methods of preparation of phospholipid depots that are injectable through a fine needle.

Priority: US20090288220P Applic. Date: 2009-12-18

Inventor: CHEN ANDREW XIAN [US]; CHEN HAILIANG [US]


Publication No.: WO2011075725A1  Published: 23/Jun/2011

Title: METHODS AND COMPOSITIONS RELATED TO CLOT-BINDING COMPOUNDS

Applicant/Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE

Application No.: US2010/061302   Filing Date: 20/Dec/2010

Abstract:Disclosed are compositions and methods related to clot-binding compounds. For example, disclosed are compositions comprising a surface molecule and at least one modified clot-binding compound. The modified clot-binding compound can selectively bind to clotted plasma protein, wherein the composition causes clotting and amplifies the accumulation of the composition in tumors. The modified clot-binding compound can enhance the clotting in tumors compared to its unmodified derivative. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.

Priority: US20090288083P Applic. Date: 2009-12-18

Inventor: RUOSLAHTI ERKKI [US]; AGEMY LILACH [US]; KOTAMRAJU VENKATA RAMANA [US]


Publication No.: WO2011075848A1  Published: 30/Jun/2011

Title: EPSILON-POLY-LYSINE CAPSULES

Applicant/Assignee: MICROPHARMA LIMITED

Application No.: CA2010/002057   Filing Date: 22/Dec/2010

Abstract:The present disclosure relates to capsules having a core and one or more capsular walls surrounding the core, wherein at least one of the capsular walls comprises a polymer comprising epsilon-poly-lysine or a derivative thereof.

Priority: US20090289727P Applic. Date: 2009-12-23; WO2010CA00660 Applic. Date: 2010-04-30

Inventor: MARTONI CHRISTOPHER JOHN [CA]; JONES MITCHELL LAWRENCE [CA]; PRAKASH SATYA [CA]


Publication No.: WO2011077158A1  Published: 30/Jun/2011

Title: ANTICOAGULANT COMPOUNDS AND THEIR USE

Applicant/Assignee: HAOMAMEDICA LIMITED

Application No.: GB2010/052194   Filing Date: 22/Dec/2010

Abstract:According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use as an anticoagulant.

Priority: GB20090022510 Applic. Date: 2009-12-23

Inventor: HODGES STEPHEN [GB]; SOPER ROBIN [GB]


Publication No.: WO2011078700A1  Published: 30/Jun/2011

Title: TOPICAL ORAL GEL FORMULATIONS FOR DENTAL USE

Applicant/Assignee:

Application No.: NZ2010/000256   Filing Date: 17/Dec/2010

Abstract:The invention relates to a composition, in the form of a gel, comprising tranexamic acid for topical oral application to a tooth extraction site either before, during or after the tooth extraction to control dental bleeding, to treat or prevent alveolar osteitis, or to produce or maintain a blood clot. The composition may comprise additional components such as chlorhexidine, methyl cellulose, a sweetener, a flavouring agent (e.g. mint), and a preservative (e.g. potassium sorbate).

Priority: NZ20090582165 Applic. Date: 2009-12-17

Inventor: MACALISTER DON [NZ]


Publication No.: WO2011079261A2  Published: 30/Jun/2011

Title: TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO HGF

Applicant/Assignee: CURNA, INC

Application No.: US2010/061996   Filing Date: 23/Dec/2010

Abstract:The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Hepatocyte Growth Factor (HGF), in particular, by targeting natural antisense polynucleotides of Hepatocyte Growth Factor (HGF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of HGF.

Priority: US20090289647P Applic. Date: 2009-12-23

Inventor: COLLARD JOSEPH [US]; KHORKOVA SHERMAN OLGA [US]


Publication No.: WO2011079302A2  Published: 30/Jun/2011

Title: SWALLOWABLE DRUG DELIVERY DEVICE AND METHODS OF DRUG DELIVERY

Applicant/Assignee: INCUBE LABS, LLC

Application No.: US2010/062070   Filing Date: 23/Dec/2010

Abstract:Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Priority: US20090284766P Applic. Date: 2009-12-24; US20100340331P Applic. Date: 2010-03-15; US20100395304P Applic. Date: 2010-05-10

Inventor: IMRAN MIR [US]


Publication No.: WO2011080401A1  Published: 07/Jul/2011

Title: RECEPTOR TYROSINE KINASE-BINDING COMPOSITIONS

Applicant/Assignee: LICENTIA LTD

Application No.: FI2010/051101   Filing Date: 31/Dec/2010

Abstract:Provided herein are compositions comprising a first binding construct which specifically binds to a first epitope of a Receptor Tyrosine Kinase (RTK) and a second binding construct which binds to a second epitope of the RTK, wherein the second epitope is different from the first epitope, wherein each of the first and second binding constructs reduces ligand-induced activation of the RTK. In specific embodiments, the RTK is a receptor for a Vascular Endothelial Growth Factor (VEGF) or a Platelet-Derived Growth Factor (PDGF). Further provided herein are methods of inhibiting cellular activities, including inhibiting cell growth (e.g., tumor or cancer cell growth), which activities are mediated by the RTK. The methods comprise contacting an RTK-expressing cell with the composition of the present disclosures.

Priority: US20100406751P Applic. Date: 2010-10-26; US20100362988P Applic. Date: 2010-07-09; US20090291755P Applic. Date: 2009-12-31

Inventor: ALITALO KARI [FI]; ANISIMOV ANDREY [FI]; TVOROGOV DENIS [FI]; LEPPAENEN VELI-MATTI [FI]


Publication No.: WO2011082164A1  Published: 07/Jul/2011

Title: MODULAR BIOCOMPATIBLE MATERIALS FOR MEDICAL DEVICES AND USES THEREOF

Applicant/Assignee: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION

Application No.: US2010/062229   Filing Date: 28/Dec/2010

Abstract:The present disclosure is directed to a method of producing nitric oxide comprising (i) providing a composition comprising a metal-organic framework, and (ii) exposing the composition to a nitric oxide-releasing compound. The disclosure also is directed to compositions, coatings, and medical devices comprising a metal-organic framework.

Priority: US20090290316P Applic. Date: 2009-12-28

Inventor: REYNOLDS MELISSA M [US]; REYNOLDS BENJAMIN P [US]


Publication No.: WO2011082432A1  Published: 07/Jul/2011

Title: MULTIFUNCTIONAL DEGRADABLE NANOPARTICLES WITH CONTROL OVER SIZE AND FUNCTIONALITIES

Applicant/Assignee: VANDERBILT UNIVERSITY

Application No.: US2011/020148   Filing Date: 04/Jan/2011

Abstract:In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymers and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Priority: US2010-651710 Applic. Date: 2010-01-04

Inventor: HARTH EVA M [US]; CALKINS DAVID J [US]; VAN DER ENDE ALICE E [US]


Publication No.: WO2011083467A1  Published: 14/Jul/2011

Title: COMBINED TREATMENT UTILIZING VB-201

Applicant/Assignee: VASCULAR BIOGENICS LTD

Application No.: IL2011/000010   Filing Date: 05/Jan/2011

Abstract:Methods of treatment which utilize co-administration of the oxidized lipid VB-201 with an additional therapeutically active agent are described herein. Methods of treating a cardiovascular disease are described herein, comprising co-administration of VB-201 and a statin to a subject who is not fully responsive to the statin, as well as methods of treating an inflammatory disease or disorder, comprising co-administration of VB-201 and glatiramer acetate. A pharmaceutical composition comprising VB-201, identified for use in combination with glatiramer acetate, is also described herein. Methods of determining a therapeutically effective amount of VB-201 in a subject and of determining a therapeutically effective amount of VB-201 for co-administration with an additional therapeutically active agent are also described. Novel unit dosage forms of VB-201 and methods utilizing same are also disclosed.

Priority: US20100423112P Applic. Date: 2010-12-15; US20100389318P Applic. Date: 2010-10-04; US20100351975P Applic. Date: 2010-06-07; US20100282250P Applic. Date: 2010-01-07; US20100292226P Applic. Date: 2010-01-05

Inventor: COHEN YAEL [IL]; YACOV NIVA [IL]; BREITBART EYAL [IL]


Publication No.: WO2011084507A1  Published: 14/Jul/2011

Title: TREATMENT OF NASAL AND SINUS DISORDERS

Applicant/Assignee:

Application No.: US2010/060558   Filing Date: 15/Dec/2010

Abstract:Disclosed herein are compositions and methods for treating nasal and sinus conditions, and symptoms thereof, with botulinum toxin (BoNT).

Priority: US20090286513P Applic. Date: 2009-12-15

Inventor: SANDERS IRA [US]


Publication No.: WO2011084652A2  Published: 14/Jul/2011

Title: SALTS AND CRYSTALLINE FORMS OF A FACTOR XA INHIBITOR

Applicant/Assignee: MILLENNIUM PHARMACEUTICALS, INC

Application No.: US2010/060885   Filing Date: 16/Dec/2010

Abstract:The present invention provides salts and crystalline forms of the compound 5-chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-imidazol-4-yl)methyl)thiophene-2-carboxamide, and pharmaceutical compositions and method of use thereof.

Priority: US20090287683P Applic. Date: 2009-12-17

Inventor: PANDEY ANJALI; QUEGAN LOUISA JANE


Publication No.: WO2011084653A1  Published: 14/Jul/2011

Title: CRYSTALLINE FORMS OF THE MESYLATE SALT OF A FACTOR XA INHIBITOR

Applicant/Assignee: MILLENNIUM PHARMACEUTICALS, INC

Application No.: US2010/060888   Filing Date: 16/Dec/2010

Abstract:The present invention provides crystalline forms of a mesylate salt of the compound 5-chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-imidazol-4-yl)methyl)thiophene-2-carboxamide and pharmaceutical compositions and methods thereof.

Priority: US20090287681P Applic. Date: 2009-12-17

Inventor: PANDEY ANJALI [US]; WANG JUAN [US]; LAMBING JOSEPH [US]


Publication No.: WO2011084700A1  Published: 14/Jul/2011

Title: ANTITHROMBOTIC NANOPARTICLE

Applicant/Assignee: THE WASHINGTON UNIVERSITY

Application No.: US2010/061103   Filing Date: 17/Dec/2010

Abstract:The present invention encompasses an antithrombotic nanoparticle.

Priority: US20090287582P Applic. Date: 2009-12-17

Inventor: MYERSON JACOB [US]; WICKLINE SAMUEL A [US]


Publication No.: WO2011088231A1  Published: 21/Jul/2011

Title: APYRASE THERAPY FOR BLEEDING CONDITIONS

Applicant/Assignee: APT THERAPEUTICS, INC

Application No.: US2011/021170   Filing Date: 13/Jan/2011

Abstract:This invention provides new methods of treating subjects experiencing or at risk of bleeding due to vascular injury, especially to the microvasculature and/or platelet desensitization. Examples of injury usefully treated by apyrase agents are pathophysiological conditions, ischemia reperfusion injury, injury from pharmacologic agents such as anticoagulants, antiplatelet agents, antithrombotics, thrombolytics, and/or immunosuppressants, and injury resulting from transplantation. Apyrase agents are also useful to maintain organ function when said organs are transplanted into an allogeneic recipient.

Priority: US20100294725P Applic. Date: 2010-01-13

Inventor: CHEN RIDONG [US]; JEONG SOON SEOG [US]


Publication No.: WO2011088267A1  Published: 21/Jul/2011

Title: METHODS AND COMPOSITIONS FOR TREATING BLEEDING DISORDERS

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A

Application No.: US2011/021215   Filing Date: 13/Jan/2011

Abstract:Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.

Priority: US20100335964P Applic. Date: 2010-01-14

Inventor: DOCKAL MICHAEL [AT]; EHRLICH HARTMUT [AT]; SCHEIFLINGER FRIEDRICH [AT]


Publication No.: WO2011089152A1  Published: 28/Jul/2011

Title: METHODS AND PHARMACEUTICAL COMPOSITION FOR THE PRESERVATION OF VASCULAR ENDOTHELIAL CELL BARRIER INTEGRITY

Applicant/Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Application No.: EP2011/050682   Filing Date: 19/Jan/2011

Abstract:The invention relates to an ANGPTL4 polypeptide for use in the preservation of vascular endothelial cell barrier integrity and reduction in no-reflow phenomenon with myocardial infarction.

Priority: EP20100305063 Applic. Date: 2010-01-20

Inventor: GERMAIN STEPHANE [FR]; GALAUP ARIANE [FR]; MONNOT CATHERINE [FR]; TISSIER RENAUD [FR]; GHALEH BIJAN [FR]; BERDEAUX ALAIN [FR]


Publication No.: WO2011089604A2  Published: 28/Jul/2011

Title: MATERIAL AND METHOD FOR TREATING INTERNAL CAVITIES

Applicant/Assignee: THERACOAT LTD

Application No.: IL2011/000069   Filing Date: 20/Jan/2011

Abstract:A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body.

Priority: US20100296589P Applic. Date: 2010-01-20

Inventor: ASHER HOLZER [IL]; DANIEL DORIT [IL]; MULLERAD MICHAEL [IL]; DE LA ZERDA JAIME [IL]; SHPOLANSKY URI [IL]; MALCHI NADAV [IL]; DOLLBERG YOSH [IL]; DOR TAL [IL]; YAVIN YOSSI [IL]


Publication No.: WO2011089619A2  Published: 28/Jul/2011

Title: A METHOD AND A BALLOON CATHETER ASSEMBLY FOR TREATING BIFURCATION LESIONS

Applicant/Assignee: CONCEPT MEDICAL RESEARCH PRIVATE LIMITED, ENVISION SCIENTIFIC PRIVATE LIMITED

Application No.: IN2011/000032   Filing Date: 17/Jan/2011

Abstract:The invention discloses a balloon catheter assembly for delivering nano-carriers to bifurcation lesions in one or more of a main branch and a side branch of a blood vessel bifurcation within 30 to 90 seconds. The balloon catheter assembly includes two or more balloons designed for use in the blood vessel bifurcation. A surface of one or more of the two or more balloons is coated with the nano-carriers. The nano-carriers include one or more drugs encapsulated with one or more biological agents.

Priority: IN2010MU00176 Applic. Date: 2010-01-22

Inventor: DOSHI MANISH [IN]; SHERDIWALA DIVYESH [IN]; SOJITRA PRAKASH [IN]


Publication No.: WO2011090947A2  Published: 28/Jul/2011

Title: METHODS FOR THE DIAGNOSIS AND TREATMENT OF PARKINSON'S DISEASE

Applicant/Assignee: THE MCLEAN HOSPITAL CORPORATION

Application No.: US2011/021581   Filing Date: 18/Jan/2011

Abstract:The present invention relates to methods for treatment or prevention of Parkinsons disease and associated conditions by increasing the expression Otx2 in the midbrain dopaminergic neurons of the patient. The present invention further relates to methods for the diagnosis and evaluation of Parkinsons disease. For instance, patient test samples are analyzed for the presence of one or more specific variant sequences associated with Parkinsons disease. In some embodiments, the variant is a promoter mutation in the Otx2 gene.

Priority: US20100296424P Applic. Date: 2010-01-19

Inventor: CHUNG CHEE YEUN [US]; ISACSON OLE [US]


Publication No.: WO2011090971A2  Published: 28/Jul/2011

Title: OSTEOCALCIN AS A TREATMENT FOR MALE REPRODUCTIVE DISORDERS

Applicant/Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Application No.: US2011/021634   Filing Date: 19/Jan/2011

Abstract:Methods and compositions for treating, preventing, or diagnosing disorders related to reproduction in male mammals, preferably humans, are provided. The methods generally involve modulation of the OST-PTP signaling pathway or the PTP-IB signaling pathway involving gamma-carboxylase and osteocalcin. Disorders amenable to treatment by the methods include, but are not limited to, male infertility, low sperm count, impaired sperm motility, impaired sperm viability, low testosterone levels, reduced libido, erectile dysfunction, underdevelopment of testes, and excess apoptosis in testes.

Priority: US20100296339P Applic. Date: 2010-01-19; US20100296415P Applic. Date: 2010-01-19

Inventor: KARSENTY GERARD [US]; DUCY PATRICIA F [US]


Publication No.: WO2011091305A2  Published: 28/Jul/2011

Title: INHIBITION OF AXL SIGNALING IN ANTI-METASTATIC THERAPY

Applicant/Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Application No.: US2011/022125   Filing Date: 21/Jan/2011

Abstract:Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Priority: US20100336478P Applic. Date: 2010-01-22

Inventor: GIACCIA AMATO J [US]; RANKIN ERINN BRUNO [US]; COCHRAN JENNIFER R [US]; JONES DOUGLAS [US]; KARIOLIS MIHALIS [US]; FUH KATHERINE [US]; MIAO YU [US]


Publication No.: WO2011094208A2  Published: 04/Aug/2011

Title: METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND TREATING RENAL IMPAIRMENT

Applicant/Assignee: ENDACEA, INC

Application No.: US2011/022411   Filing Date: 25/Jan/2011

Abstract:The present invention relates to methods for treating and preventing renal impairment by administering to a subject a therapeutically effective amount of an A1 adenosine receptor antagonist alone or in combination with at least one additional therapeutic agent. The invention further encompasses pharmaceutical compositions comprising an A1 adenosine receptor antagonist alone or with, at least, one additional therapeutic agent in a pharmaceutically acceptable carrier. The pharmaceutical compositions of the invention find use in methods for treating and preventing renal impairment.

Priority: US20100298316P Applic. Date: 2010-01-26

Inventor: WILSON CONSTANCE N [US]


Publication No.: WO2011094209A1  Published: 04/Aug/2011

Title: PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATONS

Applicant/Assignee: MERCK SHARP & DOHME CORP

Application No.: US2011/022412   Filing Date: 25/Jan/2011

Abstract:The present invention is directed to a composition useful for the treatment of a FAAH mediated disease, disorder or conditions comprising a FAAH inhibitor and a second activation, comprising a selected imidazole or oxazole FAAH inhibitor and a second active agent. The compositions will be useful in the treatment of a wide range of disease, disorder, or conditions including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease. In another aspect the invention discloses herein is directed to compositions useful in the treatment of neuropathic and nociceptive pain, said compositions comprising etoricoxib.

Priority: US20100299087P Applic. Date: 2010-01-28

Inventor: CHOBANIAN HARRY [US]; LIN LINUS S [US]; LIU PING [US]; CHIODA MARC D [US]; DEVITA ROBERT J [US]; NARGUND RAVI P [US]; GUO YAN [US]; HAMILL TERENCE [US]; LI WENPING [US]; HENZE DARRELL A [US]


Publication No.: WO2011094496A2  Published: 04/Aug/2011

Title: TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE

Applicant/Assignee: THE MEDICINES COMPANY, THE MEDICINES COMPANY (LEIPZIG) GMBH

Application No.: US2011/022863   Filing Date: 28/Jan/2011

Abstract:The invention provides compounds that are effective as inhibitors of human plasmin and plasma kallikrein, and that are useful for the prevention of blood loss and as components of fibrin adhesives. The invention further provides methods of making and using the compounds.

Priority: US20100299054P Applic. Date: 2010-01-28

Inventor: HEROLD PETER [CH]; DAGHISH MOHAMMED [DE]; JELAKOVIC STJEPAN [DE]; LUDWIG ALEXANDER [DE]; REICHELT CLAUDIA [DE]; SCHULZE ALEXANDER [DE]; SCHWEINITZ ANDREA [DE]


Publication No.: WO2011096887A1  Published: 11/Aug/2011

Title: STABLE SOLUTION

Applicant/Assignee: DIAPENSIA HB

Application No.: SE2011/050144   Filing Date: 08/Feb/2011

Abstract:The present invention relates to a stable solution comprising a stable solution without coagulation factor XII and with a defined amount of ionized calcium. The stable solution may be used as control material for coagulation analysis. Further, a method for producing said stable solution, as well as methods for assessing coagulation system status in a subject and kits, is encompassed herein.

Priority: US20100302196P Applic. Date: 2010-02-08; SE20100050124 Applic. Date: 2010-02-08

Inventor: LINDAHL TOMAS [SE]; FAXAELV LARS [SE]


Publication No.: WO2011100354A1  Published: 18/Aug/2011

Title: REMOVAL OF VIRULENCE FACTORS THROUGH EXTRACORPOREAL THERAPY

Applicant/Assignee: EXTHERA MEDICAL, LLC

Application No.: US2011/024229   Filing Date: 09/Feb/2011

Abstract:A method to remove virulence factors from infected blood by passing the blood through a surface cartridge with immobilized carbohydrates, such as heparin, wherein the virulence factors are toxins released from pathogens such as B. anthracis, S. aureus, and P. aeruginosa.

Priority: US20100302826P Applic. Date: 2010-02-09

Inventor: MCCREA KEITH [US]; WARD ROBERT S [US]


Publication No.: WO2011100538A1  Published: 18/Aug/2011

Title: THERAPEUTIC METHODS USING AN TI-CD200 ANTIBODIES

Applicant/Assignee: ALEXION PHARMACEUTICALS, INC

Application No.: US2011/024511   Filing Date: 11/Feb/2011

Abstract:The present disclosure relates to anti-CD200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer. Also featured are biomarkers for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and/or cancer. In addition, the disclosure features methods of treatment using an anti-CD200 antibody in combination with one or more additional therapeutic agents such as an anti-CD20 therapeutic agent.

Priority: US20100337962P Applic. Date: 2010-02-11

Inventor: ROTHER RUSSELL P [US]; YAN YAN [US]


Publication No.: WO2011101435A1  Published: 25/Aug/2011

Title: ACTIVATABLE CONSTRUCTS

Applicant/Assignee: NOVO NORDISK A/S

Application No.: EP2011/052416   Filing Date: 18/Feb/2011

Abstract:The current invention relates to a construct, a polynucleotide that encodes said construct and a cell that expresses said construct. Furthermore, the current invention relates to the use of said construct for the treatment of bleedings and their associated co-morbidities and to a method of treatment of bleedings, inflammation and metastasis of cancer cells.

Priority: US20100307606P Applic. Date: 2010-02-24; EP20100154178 Applic. Date: 2010-02-19

Inventor: BJELKE JAIS ROSE [DK]; GRELL SUSANNE NEDERGAARD [DK]; EGEBJERG THOMAS [DK]


Publication No.: WO2011103177A1  Published: 25/Aug/2011

Title: NUCLEOSIDE-CONTAINING COMPOSITIONS AND METHODS FOR TREATING RED BLOOD CELLS

Applicant/Assignee: VIACELL, LLC

Application No.: US2011/025066   Filing Date: 16/Feb/2011

Abstract:Blood storage and/or rejuvenating compositions that include D-ribose and a nucleoside other than inosine (e.g., guanosine) are disclosed herein. Such compositions can be useful in methods for treating (e.g., storing and/or rejuvenating) red blood cells.

Priority: US20100338299P Applic. Date: 2010-02-16

Inventor: ERICSON DANIEL G [US]


Publication No.: WO2011103179A1  Published: 25/Aug/2011

Title: ARGININE-CONTAINING COMPOSITIONS AND METHODS FOR TREATING RED BLOOD CELLS

Applicant/Assignee: VIACELL, LLC

Application No.: US2011/025069   Filing Date: 16/Feb/2011

Abstract:Blood storage and/or rejuvenating compositions that include D-ribose and an arginine (e.g. L-arginine, D-arginine, or a combination thereof) are disclosed herein. Such compositions can be useful in methods for treating (e.g., storing and/or rejuvenating) red blood cells.

Priority: US20100338263P Applic. Date: 2010-02-16; US20100370713P Applic. Date: 2010-08-04

Inventor: ERICSON DANIEL G [US]; THOMPSON JEFFREY A [US]


Publication No.: WO2011103462A1  Published: 25/Aug/2011

Title: METHODS OF MANUFACTURE OF IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS

Applicant/Assignee: OSIRIS THERAPEUTICS, INC

Application No.: US2011/025478   Filing Date: 18/Feb/2011

Abstract:Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Priority: US20100369562P Applic. Date: 2010-07-30; US20100338489P Applic. Date: 2010-02-18; US20100338464P Applic. Date: 2010-02-18

Inventor: TOM SAMSON [US]; DANILKOVITCH ALLA [US]; YOO DANA [US]; JANSEN TIMOTHY [US]; KUANG JIN-QIANG [US]; MARCONI JENNIFER MICHELLE [US]


Publication No.: WO2011106086A1  Published: 01/Sep/2011

Title: PEGYLATED ALBUMIN POLYMERS AND USES THEREOF

Applicant/Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: US2011/000325   Filing Date: 22/Feb/2011

Abstract:The present invention provides an albumin polymer and a process of making an albumin polymer, the process comprising breaking instrinsic disulfide bridges in albumin with a reducing agent and crosslinking inter- and intra- molecular disulfide bridges so as to form the ploymer. The present invention also provides PEGylated albumin polymers and methods of making PEGylated albumin polymers, the methods comprising polymerizing albumin by crosslinking inter- and intra- molecular disulfide bridges, and PEGylating the albumin polymer. The present invention further provides a pharmaceutical composition useful as a blood plasma expander, blood substitute or for drug delivery, and methods of treating blood loss in a subject and of delivering drugs to a subject's tissue, the pharmaceutical composition comprising a therapeutically effective amount of the PEGylated albumin polymer.

Priority: US20100339020P Applic. Date: 2010-02-25

Inventor: NACHARAJU PARIMALA [US]; INTAGLIETTA MARCOS [US]


Publication No.: WO2011106248A2  Published: 01/Sep/2011

Title: TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE

Applicant/Assignee: AUSPEX PHARMACEUTICALS, INC

Application No.: US2011/025368   Filing Date: 18/Feb/2011

Abstract:The present invention relates to new trimethoxyphenyl inhibitors of tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof. (I)

Priority: US20100307742P Applic. Date: 2010-02-24

Inventor: ZHANG CHENGZHI [US]; SOMMERS ANDREAS [US]


Publication No.: WO2011106635A1  Published: 01/Sep/2011

Title: TREATMENT OF SEPSIS USING COMPLEMENT INHIBITORS

Applicant/Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, OKLAHOMA MEDICAL RESEARCH FOUNDATION, THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA

Application No.: US2011/026229   Filing Date: 25/Feb/2011

Abstract:Methods for the treatment of sepsis with complement inhibitors are disclosed. In particular, C3 inhibitors, such as Compstatin and Compstatin analogs, are administered at various times following the onset of sepsis to alleviate tissue damage and organ failure, which are hallmarks of the second, extravascular stage of sepsis. Combination therapies for comprehensive treatment of sepsis are also disclosed. Pharmaceutical compositions and kits for use in the methods are disclosed as well.

Priority: US20100308094P Applic. Date: 2010-02-25

Inventor: LAMBRIS JOHN D [US]; TAYLOR FLETCHER B [US]; LUPU FLOREA [US]; KINASEWITZ GARY [US]


Publication No.: WO2011106645A1  Published: 01/Sep/2011

Title: DIRECT ANALYSIS OF ANTIGEN-SPECIFIC IMMUNE RESPONSE

Applicant/Assignee: BENAROYA RESEARCH INSTITUTE

Application No.: US2011/026244   Filing Date: 25/Feb/2011

Abstract:Provided herein are methods for the determination of antigen-specific CD4+ T cell phenotype and/or frequency, which is useful for detecting or monitoring immune function, directing immunotherapy to the use of those epitopes or antigen fragments that elicit an allergic reaction (e.g., as measured by detection of a Th2 response) and/or promote immune deviation, monitoring an immune response to a particular antigen, etc.

Priority: US20100308730P Applic. Date: 2010-02-26

Inventor: KWOK WILLIAM W [US]; WAMBRE ERIK [US]


Publication No.: WO2011106775A2  Published: 01/Sep/2011

Title: DERIVATION OF HEMATOPOIETIC CELLS FROM ADULT MESENCHYMAL STEM CELLS

Applicant/Assignee:

Application No.: US2011/026486   Filing Date: 28/Feb/2011

Abstract:Methods and compositions for differentiating tissue resident multipotent mesenchmal stromal cells (MSCs) such as adipose tissue resident MSCs into a hematopoietic lineage are described.

Priority: US20100308931P Applic. Date: 2010-02-27

Inventor: IZADPANAH REZA [US]; ALT ECKHARD U [US]


Publication No.: WO2011107591A1  Published: 09/Sep/2011

Title: CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION

Applicant/Assignee: RIGSHOSPITALET, KOEBENHAVNS UNIVERSITET, SYDDANSK UNIVERSITET

Application No.: EP2011/053309   Filing Date: 04/Mar/2011

Abstract:The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.

Priority: EP20100155621 Applic. Date: 2010-03-05; US20100311024P Applic. Date: 2010-03-05

Inventor: GARRED PETER [DK]; GLUE TINA HUMMELSHOEJ [DK]; SKJOEDT MIKKEL-OLE [DK]


Publication No.: WO2011109112A2  Published: 09/Sep/2011

Title: METHOD OF DETECTING TAU PROTEIN AND TAU FRAGMENTS IN SERUM

Applicant/Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY

Application No.: US2011/000419   Filing Date: 04/Mar/2011

Abstract:The present invention provides quantitative methods for the detection of tau protein and/or tau fragments. More specifically, the present invention provides quantitative methods for diagnosing a tauopathy or ruling out a tauopathy as the cause of disease, particularly the diagnosis and ruling of Alzheimer's disease. The present invention further provides a method for diagnosing a tauopathy by computing the ratio of two detected tau proteins or tau fragments.

Priority: US20100311140P Applic. Date: 2010-03-05

Inventor: DEBERNARDIS JOHN F [US]; ZINKOWSKI RAYMOND P [US]


Publication No.: WO2011109334A2  Published: 09/Sep/2011

Title: LOCALIZATION OF AGENTS AT A TARGET SITE WITH A COMPOSITION AND AN ENERGY SOURCE

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: US2011/026592   Filing Date: 01/Mar/2011

Abstract:A method for localizing delivery of an agent to a target site in a subject is provided. The method allows accumulation and/or release of the agent at the target site in the subject through the use of an energy source.

Priority: US20100309374P Applic. Date: 2010-03-01

Inventor: FERRARA KATHERINE W [US]; KHEIROLOMOOM AZADEH [US]


Publication No.: WO2011109356A2  Published: 09/Sep/2011

Title: ANTI-COAGULANT INFUSION FLUID SOURCE

Applicant/Assignee: EDWARDS LIFESCIENCES CORPORATION

Application No.: US2011/026630   Filing Date: 01/Mar/2011

Abstract:Methods and systems for preventing or eliminating blood coagulation or thrombus during use of an intravenous anti-thrombotic sensor are disclosed. The method further comprises for providing antimicrobial into the infusion fluid source. An anti-thrombotic sensor is also disclosed that comprises a coating of a complex of a non-heparin anti-thrombotic agent and an alkylbenzyldimethyl ammonium cationic salt.

Priority: US20100310236P Applic. Date: 2010-03-03

Inventor: PETISCE JAMES [US]; OLIN JANE [US]; PASTER EDEN [US]; TRINH KRISTIE [US]


Publication No.: WO2011109768A2  Published: 09/Sep/2011

Title: COMPOSITIONS AND METHODS FOR MODULATING CARDIAC CONDITIONS

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODYCORPORATE, VIRGINIA COMMONWEALTH UNIVERSITY

Application No.: US2011/027283   Filing Date: 04/Mar/2011

Abstract:Embodiments herein report methods and compositions for treating cardiac conditions. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating a subject having or suspected of undergoing cardiac remodeling after a cardiac event. Other embodiments herein relate to compounds including naturally occurring and synthetic compositions of alpha-1 antitrypsin and fragments thereof.

Priority: US20100312589P Applic. Date: 2010-03-10; US20100310645P Applic. Date: 2010-03-04

Inventor: DINARELLO CHARLES A [US]; ABBATE ANTONIO [US]; LEWIS ELI C [IL]


Publication No.: WO2011112229A2  Published: 15/Sep/2011

Title: THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE

Applicant/Assignee: INCUBE LABS, LLC

Application No.: US2010/062073   Filing Date: 23/Dec/2010

Abstract:Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to an actuator having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall.

Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Priority: US20100339941P Applic. Date: 2010-03-10

Inventor: IMRAN MIR A [US]


Publication No.: WO2011112873A2  Published: 15/Sep/2011

Title: EXTRACORPOREAL IMMUNOADSORPTION TREATMENT

Applicant/Assignee:

Application No.: US2011/027997   Filing Date: 10/Mar/2011

Abstract:A method for extracorporeally administering selected biologic agents that target soluble cytokines and chemokines via immunoapheresis in order to treat patients with a variety of acute or chronic autoimmune and inflammatory disease states.

Priority: US20100312558P Applic. Date: 2010-03-10

Inventor: TEBBEY PAUL [US]


Publication No.: WO2011115479A1  Published: 22/Sep/2011

Title: USE OF ANTICOAGULANTS IN THE PRODUCTION OF RECOMBINANT PROTEINS IN THE MILK OF TRANSGENIC ANIMALS

Applicant/Assignee: PHARMING INTELLECTUAL PROPERTY BV

Application No.: NL2011/050166   Filing Date: 11/Mar/2011

Abstract:The invention relates to the production of recombinant human fibrinogen (rhFib) in the milk of transgenic mammalian animals. This production and subsequent purification process is generally hampered by the occurrence of so-called 'clots' and 'flakes' in the milk which, in severe cases, may prevent the cow from being milked at all, resulting in a halt of lactation. These clots and flakes occur because of the expression of the fibrinogen protein, which is a factor that is normally involved in blood clotting. The invention relates to solving this milk clotting problem by treating the (lactating) animals with anticoagulants such as coumarines. A preferred anticoagulant that is used in the methods of the present invention is warfarin.

Priority: US20100387665P Applic. Date: 2010-09-29; US20100314673P Applic. Date: 2010-03-17; EP20100156751 Applic. Date: 2010-03-17

Inventor: NELSON KATHRYN MARGARET [US]; MOSESSON MICHAEL WILLIAM [US]; PUSATERI ANTHONY [US]; FORSBERG ERIK JORDAHL [US]


Publication No.: WO2011115712A2  Published: 22/Sep/2011

Title: TFPI INHIBITORS AND METHODS OF USE

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEAL THCARE S.A, 3B PHARMACEUTICALS GMBH

Application No.: US2011/024604   Filing Date: 11/Feb/2011

Abstract:The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.

Priority: US20100315758P Applic. Date: 2010-03-19

Inventor: DOCKAL MICHAEL [AT]; HARTMANN RUDOLF [AT]; FRIES MARKUS [AT]; SCHEIFLINGER FRIEDRICH [AT]; EHRLICH HARTMUT [AT]; REINEKE ULRICH [DE]; OSTERKAMP FRANK [DE]; POLAKOWSKI THOMAS [DE]


Publication No.: WO2011115804A1  Published: 22/Sep/2011

Title: SGC STIMULATORS

Applicant/Assignee: IRONWOOD PHARMACEUTICALS, INC

Application No.: US2011/027824   Filing Date: 10/Mar/2011

Abstract:Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.

Priority: US201161446777P Applic. Date: 2011-02-25; US20100314966P Applic. Date: 2010-03-17

Inventor: MOORE JOEL [US]; JIA JAMES [US]; NAKAI TAKASHI [US]; KIM CHARLES [US]; LEE THOMAS WAI-HO [US]; YANG JANE [US]


Publication No.: WO2011116132A1  Published: 22/Sep/2011

Title: HETEROGENEOUS IMPLANTABLE DEVICES FOR DRUG DELIVERY

Applicant/Assignee: TITAN PHARMACEUTICALS, INC

Application No.: US2011/028727   Filing Date: 16/Mar/2011

Abstract:The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.

Priority: US20100314465P Applic. Date: 2010-03-16

Inventor: PATEL RAJESH A [US]; BHONSLE SUNIL R [US]


Publication No.: WO2011123013A1  Published: 06/Oct/2011

Title: METHOD FOR DIAGNOSING AND CREATING IMMUNOGENIC TOLERANCE IN CONTACT ALLERGY AND OTHER EPITHELIAL IMMUNOTOXICOLOGICAL AILMENTS

Applicant/Assignee:

Application No.: SE2011/000058   Filing Date: 29/Mar/2011

Abstract:A method is provided for diagnosis and induction of immunogenic tolerance in contact allergy and other epithelial immunotoxicological ailments, based on knowledge the role that keratinocytes play in these ailments and it is of importance for several conditions, including but not limited to allergic contact dermatitis (ACD), drug hypersensitivity reactions (DHRs) and autoimmune diseases.

Priority: US20100341359P Applic. Date: 2010-03-29

Inventor: BROO KERSTIN [SE]; ANDERSSON SOFIA [SE]; STENFELDT ANNA-LENA [SE]; JONSSON CHARLOTTE [SE]


Publication No.: WO2011123524A2  Published: 06/Oct/2011

Title: MACROLIDE INHIBITORS OF MTOR

Applicant/Assignee: AUSPEX PHARMACEUTICAL, INC

Application No.: US2011/030507   Filing Date: 30/Mar/2011

Abstract:The present invention relates to new macrolide inhibitors of mTOR, pharmaceutical compositions thereof, and methods of use thereof (Formula I).

Priority: US20100319665P Applic. Date: 2010-03-31

Inventor: ZHANG CHENGZHI [US]


Publication No.: WO2011126903A2  Published: 13/Oct/2011

Title: MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN

Applicant/Assignee: VERSEON, INC

Application No.: US2011/030585   Filing Date: 30/Mar/2011

Abstract:There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.

Priority: US20100319175P Applic. Date: 2010-03-30

Inventor: SHORT KEVIN MICHAEL [US]; PHAM SON MINH [US]; WILLIAMS DAVID CHARLES [US]; DATTA SOMALEE [US]


Publication No.: WO2011127071A1  Published: 13/Oct/2011

Title: PLATELET RICH PLASMA FORMULATIONS

Applicant/Assignee:

Application No.: US2011/031277   Filing Date: 05/Apr/2011

Abstract:Compositions for platelet rich plasma (PRP) and neutrophil-depleted PRP are provided. Methods for treating ischemia damaged tissues by delivering a PRP composition, in some embodiments a neutrophil-depleted PRP composition to the damaged tissue are provided. In some variations, the compositions may be useful to treat ischemic heart disease and repair damaged cardiovascular tissue following acute myocardial infarction including congestive heart failure. In some variations, the compositions may be useful to reduce cardiac apoptosis after a heart attack.

Priority: US20100351178P Applic. Date: 2010-06-03; US20100320862P Applic. Date: 2010-04-05

Inventor: MISHRA ALLAN [US]


Publication No.: WO2011127117A1  Published: 13/Oct/2011

Title: ANGIOGENESIS USING PLACENTAL STEM CELLS

Applicant/Assignee: ANTHROGENESIS CORPORATION

Application No.: US2011/031335   Filing Date: 06/Apr/2011

Abstract:Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.

Priority: US20100321822P Applic. Date: 2010-04-07

Inventor: ABBOT STEWART [US]; EDINGER JAMES [US]; FRANCKI ALEKSANDER [US]; HARIRI ROBERT J [US]; JANKOVIC VLADIMIR [US]; KAPLUNOVSKY ALEKSANDR [US]; LABAZZO KRISTEN [US]; LAW ERIC [US]; PADLIYA NEERAV [US]; PAREDES JENNIFER [US]; WANG JIA-LUN [US]


Publication No.: WO2011127174A1  Published: 13/Oct/2011

Title: STRAINS OF XENOTROPIC MURINE LEUKEMIA-RELATED VIRUS AND METHODS FOR DETECTION THEREOF

Applicant/Assignee: WHITTEMORE PETERSON INSTITUTE FOR NEURO-IMMUNE DISEASE

Application No.: US2011/031423   Filing Date: 06/Apr/2011

Abstract:Provided are novel strains of Xenotropic Murine Leukemia Virus-Related Virus (XMRV), or polynucleotides or polypeptides thereof. Identified herein are nucleic acid changes or amino acid changes identified in XMRV strains isolated from subjects. Also provided are methods of detecting such XMRV strains based at least in part on the identified nucleic acid changes or amino acid changes.

Priority: US20100358734P Applic. Date: 2010-06-25; US20100321147P Applic. Date: 2010-04-06

Inventor: MIKOVITS JUDY A [US]; LOMBARDI VINCENT C [US]


Publication No.: WO2011127337A2  Published: 13/Oct/2011

Title: TREATMENT OF FIBROBLAST GROWTH FACTOR 21 (FGF21) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO FGF21

Applicant/Assignee: OPKO CURNA LLC

Application No.: US2011/031665   Filing Date: 08/Apr/2011

Abstract:The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Fibroblast growth factor 21 (FGF21), in particular, by targeting natural antisense polynucleotides of Fibroblast growth factor 21 (FGF21). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of FGF21.

Priority: US20100322352P Applic. Date: 2010-04-09

Inventor: COLLARD JOSEPH [US]; KHORKOVA SHERMAN OLGA [US]


Publication No.: WO2011127405A1  Published: 13/Oct/2011

Title: METHODS AND COMPOSITIONS FOR ENHANCED DELIVERY OF COMPOUNDS

Applicant/Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, THE SALK INSTITUTE OF BIOLOGICAL STUDIES

Application No.: US2011/031785   Filing Date: 08/Apr/2011

Abstract:Disclosed are compositions and methods related to multivalent compositions targeted to cells and tissues. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.

Priority: US20100322207P Applic. Date: 2010-04-08; US20100376856P Applic. Date: 2010-08-25

Inventor: RUOSLAHTI ERKKI [US]; AGEMY LILACH [US]; FRIEDMANN-MORVINSKI DINORAH [US]; KOTAMRAJU VENKATA RAMANA [US]; SUGAHARA KAZUKI [US]; VERMA INDER [US]


Publication No.: WO2011127470A1  Published: 13/Oct/2011

Title: COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION WITHOUT HLA MATCHING

Applicant/Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER

Application No.: US2011/031953   Filing Date: 11/Apr/2011

Abstract:The present invention relates to methods and compositions for providing hematopoietic function in immunodeficient human patients, by selecting an expanded human umbilical cord blood stem/progenitor cell sample without taking into account the HLA-type of the expanded human cord blood stem/progenitor sample or the HLA-type of the patient

and administering the selected expanded human cord blood stem/progenitor cell sample to the patient. Methods for obtaining the expanded human cord blood stem/progenitor cell samples, banks of frozen expanded human cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein.

Priority: US20100322544P Applic. Date: 2010-04-09

Inventor: BERNSTEIN IRWIN D [US]; DELANEY COLLEEN [US]


Publication No.: WO2011127472A1  Published: 13/Oct/2011

Title: COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION

Applicant/Assignee: FRED HUTCHINSON CANCER RESEARCH CENTER

Application No.: US2011/031957   Filing Date: 11/Apr/2011

Abstract:The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the HLA antigens or alleles typed in the patient

and administering the selected pool of expanded human cord blood stem/progenitor cell samples to the patient. Methods for obtaining the pools of expanded human cord blood stem/progenitor cell samples, banks of frozen pools of expanded human umbilical cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein.

Priority: US20100322575P Applic. Date: 2010-04-09

Inventor: BERNSTEIN IRWIN D [US]; DELANEY COLLEEN [US]


Publication No.: WO2011130479A2  Published: 20/Oct/2011

Title: APPLICATION OF POLYMERIC MATERIALS TO SCREENS TO FACILITATE HEMOSTASIS AND WOUND HEALING

Applicant/Assignee: MARINE POLYMER TECHNOLOGIES, INC

Application No.: US2011/032434   Filing Date: 14/Apr/2011

Abstract:This invention relates in general to a method and device for facilitating hemostasis and wound healing. In particular, the invention relates to the device comprising a polymeric material disposed on a scaffold that facilitates hemostasis and wound healing. Specifically, the invention contemplates the use of such scaffolds in conjunction with a negative pressure device.

Priority: US2010-761837 Applic. Date: 2010-04-16

Inventor: ORGILL DENNIS P [US]; PIETRAMAGGIORI GIORGIO [IT]; FINKIELSZTEIN SERGIO [US]; VOURNAKIS JOHN N [US]


Publication No.: WO2011130729A2  Published: 20/Oct/2011

Title: METHODS FOR TREATING METABOLIC DISORDERS USING FGF

Applicant/Assignee: SALK INSTITUTE FOR BIOLOGICAL STUDIES

Application No.: US2011/032848   Filing Date: 18/Apr/2011

Abstract:The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.

Priority: US20100325253P Applic. Date: 2010-04-16; US20100325261P Applic. Date: 2010-04-16; US20100325255P Applic. Date: 2010-04-16

Inventor: JONKER JOHAN W [US]; DOWNES MICHAEL [US]; EVANS RONALD M [US]; SUH JAEMYOUNG [US]


Publication No.: WO2011133052A2  Published: 27/Oct/2011

Title: USE OF THE MODIFIED POLYSACCHARIDES FOR HEPARIN NEUTRALIZATION

Applicant/Assignee: UNIWERSYTET JAGIELLONSKI

Application No.: PL2011/000040   Filing Date: 20/Apr/2011

Abstract:The subject of the invention is the use of cationically modified polysaccharides, except for chitosan, for direct neutralization of heparin in blood and physiological fluids in a mammal. Cationic modification of the polysaccharides is achieved using compound containing cationic ammonium groups and/or the polysaccharides are grafted with a polymer containing amine and/or ammonium groups.

Priority: PL20100391043 Applic. Date: 2010-04-22

Inventor: NOWAKOWSKA MARIA [PL]; SZCZUBIALKA KRZYSZTOF [PL]; KAMINSKI KAMIL [PL]


Publication No.: WO2011133653A1  Published: 27/Oct/2011

Title: INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS

Applicant/Assignee: MARS, INCORPORATED

Application No.: US2011/033223   Filing Date: 20/Apr/2011

Abstract:Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity : Formule (I), (II) where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

Priority: US20100326892P Applic. Date: 2010-04-22; US20100413202P Applic. Date: 2010-11-12

Inventor: VAN ZANDT MICHAEL [US]; GOLEBIOWSKI ADAM [US]; JI MIN KOO [US]; WHITEHOUSE DARREN [US]; RYDER TODD [US]; BECKETT PAUL [US]


Publication No.: WO2011135308A1  Published: 03/Nov/2011

Title: CONJUGATED BLOOD COAGULATION FACTOR VIIA

Applicant/Assignee: LEVERTON LICENCE HOLDINGS LIMITED

Application No.: GB2011/000663   Filing Date: 28/Apr/2011

Abstract:The present invention provides a biocompatible polymer conjugated to FVIIa via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in FVIIa, and pharmaceutical compositions comprising such conjugated forms of FVIIa.

Priority: GB20100007356 Applic. Date: 2010-04-30

Inventor: HENRY WILLIAM [GB]


Publication No.: WO2011139387A1  Published: 10/Nov/2011

Title: TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)

Applicant/Assignee: OPKO CURNA, LLC

Application No.: US2011/021052   Filing Date: 13/Jan/2011

Abstract:The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.

Priority: US20100415891P Applic. Date: 2010-11-22; US20100412066P Applic. Date: 2010-11-10; US20100409136P Applic. Date: 2010-11-02; US20100330427P Applic. Date: 2010-05-03

Inventor: COLLARD JOSEPH [US]; KHORKOVA SHERMAN OLGA [US]; COITO CARLOS [US]; DE LEON BELINDA [US]


Publication No.: WO2011139838A2  Published: 10/Nov/2011

Title: INTRANASAL FORMULATIONS

Applicant/Assignee: ZELOS THERAPEUTICS, INC

Application No.: US2011/034335   Filing Date: 28/Apr/2011

Abstract:The present disclosure relates to compositions and methods for treating bone deficit disorders in a subject in need thereof comprising intranasally administering a pharmaceutically effective amount of a PTH-related peptidic analogue and a transmucosal absorption enhancer.

Priority: US20100328894P Applic. Date: 2010-04-28

Inventor: MACDONALD BRIAN [US]; MERUTKA GENE SCOTT [US]


Publication No.: WO2011140190A1  Published: 10/Nov/2011

Title: TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE

Applicant/Assignee: INFINITY PHARMACEUTICALS

Application No.: US2011/035141   Filing Date: 04/May/2011

Abstract:Provided herein are tetrazolone FASN inhibitors of the formula (I): (I) or a pharmaceutically acceptable form thereof

wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Priority: US20100419174P Applic. Date: 2010-12-02; US201161472566P Applic. Date: 2011-04-06; US201161437564P Applic. Date: 2011-01-28; US20100331644P Applic. Date: 2010-05-05; US20100331575P Applic. Date: 2010-05-05

Inventor: BAHADOOR ADILAH [US]; CASTRO ALFREDO C [US]; CHAN LAWRENCE K [US]; KEANEY GREGG F [US]; NEVALAINEN MARTA [US]; NEVALAINEN VESA [US]; PELUSO STEPHANE [US]; SNYDER DANIEL A [US]; TIBBITTS THOMAS T [US]


Publication No.: WO2011140296A1  Published: 10/Nov/2011

Title: TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE

Applicant/Assignee: INFINITY PHARMACEUTICALS

Application No.: US2011/035291   Filing Date: 05/May/2011

Abstract:Provided herein are triazole FASN inhibitors of the formula (I): (I) or a pharmaceutically acceptable form thereof

wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.

Priority: US20100331632P Applic. Date: 2010-05-05

Inventor: BAHADOOR ADILAH [US]; CASTRO ALFREDO C [US]; CHAN LAWRENCE K [US]; KEANEY GREGG F [US]; NEVALAINEN MARTA [US]; NEVALAINEN VESA [US]; PELUSO STEPHANE [US]; TIBBITTS THOMAS T [US]


Publication No.: WO2011140654A1  Published: 17/Nov/2011

Title: POOLED CORD BLOOD UNITS

Applicant/Assignee: MCGILL UNIVERSITY HEALTH CENTER

Application No.: CA2011/050288   Filing Date: 10/May/2011

Abstract:A pharmaceutical composition comprising hematopoietic stem cells isolated from pooled umbilical cord blood from separate donors, which can be infused in a patient in need of an umbilical cord blood transplant to increase the speed and success of engraftment. A method and a pooling criteria for increasing yield or minimizing lysis of total nucleated cells in pooled umbilical cord blood from separate donors is also provided. The method involves considering the ABO blood types of the donors of the umbilical cord blood units to be pooled as well as the ABO blood type of the respective mothers. The present invention also provides a means for increasing the availability of cord blood transplants to adults or individuals greater than 65 or 70 kilograms.

Priority: CA20102703428 Applic. Date: 2010-05-11; US20100333491P Applic. Date: 2010-05-11

Inventor: PELTIER LINDA [CA]; LANEUVILLE PIERRE [CA]


Publication No.: WO2011143475A1  Published: 17/Nov/2011

Title: LANTHANUM CARBONATE HYDROXIDE, LANTHANUM OXYCARBONATE AND METHODS OF THEIR MANUFACTURE AND USE

Applicant/Assignee: SPECTRUM PHARMACEUTICALS, INC

Application No.: US2011/036317   Filing Date: 12/May/2011

Abstract:The present invention is a method of producing a lanthanum carbonate hydroxide or lanthanum oxycarbonate which has improved properties. The method involves the use of a water soluble lanthanum and a water soluble non-alkali metal carbonate or bicarbonate. The resulting material can be used as a phosphate binder individually or for treating patients with hyperphosphatemia.

Priority: US20100333887P Applic. Date: 2010-05-12

Inventor: DIXIT MILIND [US]; GORE ASHOK YESHWANT [US]; MAHALINGAM RAVICHANDRAN [US]; SCHAUER EDWARD A [US]; STEWART MATTHEW [US]; TANDALE RAJENDRA [US]


Publication No.: WO2011143538A1  Published: 17/Nov/2011

Title: EXTRACORPOREAL DEVICES AND METHODS OF TREATING COMPLICATIONS OF PREGNANCY

Applicant/Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER

Application No.: US2011/036409   Filing Date: 13/May/2011

Abstract:The invention features extracorporeal methods for the treatment of a subject having a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia. The invention also features devices used for the extracorporeal treatment of subjects have a pregnancy related hypertensive disorder, such as pre-eclampsia or eclampsia.

Priority: US20100346216P Applic. Date: 2010-05-19; US20100334824P Applic. Date: 2010-05-14

Inventor: KARUMANCHI ANANTH S [US]


Publication No.: WO2011146574A1  Published: 24/Nov/2011

Title: IL-12 FORMULATIONS FOR ENHANCING HEMATOPOIESIS

Applicant/Assignee: NEUMEDICINES, INC

Application No.: US2011/036936   Filing Date: 18/May/2011

Abstract:Provided are formulations for proteins to be injected into mammals. Specifically, formulations for recombinant IL-12 in mice and primates.

Priority: US20100345986P Applic. Date: 2010-05-18

Inventor: BASILE LENA A [US]


Publication No.: WO2011146704A1  Published: 24/Nov/2011

Title: DEGRADABLE CLOSTRIDIAL TOXINS

Applicant/Assignee: ALLERGAN, INC

Application No.: US2011/037131   Filing Date: 19/May/2011

Abstract:The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.

Priority: US20100346578P Applic. Date: 2010-05-20

Inventor: STEWARD LANCE E [US]; GHANSHANI SANJIV [US]; FERNANDEZ-SALAS ESTER [US]; GILMORE MARCELLA A [US]; FRANCIS JOSEPH [US]; AOKI KEI ROGER [US]


Publication No.: WO2011146981A1  Published: 01/Dec/2011

Title: ANTI-DIABETIC COMPOSITIONS AND METHODS

Applicant/Assignee: OZSTAR THERAPEUTICS PTY LTD

Application No.: AU2011/000622   Filing Date: 24/May/2011

Abstract:The present invention is concerned with synergistic compositions effective in the treatment of diabetes. In particular, the present invention is concerned with synergistic compositions comprising inulin, or a suitable source thereof, and Sulphonylureas used in the treatment of type-2 Diabetes Mellitus (T2DM) and hyperglyacemia.

Priority: AU20100902262 Applic. Date: 2010-05-24

Inventor: GORGANI NICK NASER [AU]; AFKHAM MAHNOOSH [AU]


Publication No.: WO2011148326A1  Published: 01/Dec/2011

Title: VIRALLY-INACTIVATED GROWTH FACTORS-CONTAINING PLATELET LYSATE DEPLETED OF PDGF AND VEGF AND PREPARATION METHOD THEREOF

Applicant/Assignee: GWO REI BIOMEDICAL TECHNOLOGY CORP

Application No.: IB2011/052278   Filing Date: 25/May/2011

Abstract:There is an increasing interest in human platelet extracts rich in growth factors (PGF) both for wound healing and for stem cell expansion. The present invention concerns a virally- inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF, which is preferably enriched in TGF, IGF and EGF-rich. The present invention further concerns a method for obtaining such a platelet lysate, comprising the steps of contacting a starting platelet concentrate with a solvent and/or a detergent, incubating said starting platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2 DEG C to 50 DEG C, optionally removing the solvent and/or the detergent by oil extraction and obtaining an aqueous protein phase

and incubating the solvent and/or detergent- treated platelet concentrate or the aqueous protein phase with charcoal.

Priority: EP20100163843 Applic. Date: 2010-05-25

Inventor: BURNOUF THIERRY [FR]; SU CHENG-YAO [TW]


Publication No.: WO2011149110A1  Published: 01/Dec/2011

Title: NOVEL COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF THROMBOEMBOLISM

Applicant/Assignee: DAIICHI SANKYO COMPANY, LIMITED

Application No.: JP2011/062645   Filing Date: 26/May/2011

Abstract:An object of the present invention is to find a novel pharmaceutical drug combination that does not promote the risk of bleeding as adverse reaction and is useful in the prevention and/or treatment of thrombus and/or embolism. The present invention provides a pharmaceutical composition comprising N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide represented by the formula (I): or a pharmacologically acceptable salt thereof, or a solvate thereof, and clopidogrel or a pharmacologically acceptable salt thereof, or a solvate thereof. The present invention also provides a kit comprising: a pharmaceutical composition comprising N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide represented by the formula (I) or a pharmacologically acceptable salt thereof, or a solvate thereof

and a pharmaceutical composition comprising clopidogrel or a pharmacologically acceptable salt thereof, or a solvate thereof

which may be packaged separately.

Priority: JP20100122761 Applic. Date: 2010-05-28

Inventor: MORISHIMA YOSHIYUKI


Publication No.: WO2011149964A2  Published: 01/Dec/2011

Title: METHODS FOR TREATING OR PREVENTING VASCULAR GRAFT FAILURE

Applicant/Assignee: MOERAE MATRIX, INC.,

Application No.: US2011/037776   Filing Date: 24/May/2011

Abstract:The described invention provides pharmaceutical compositions and methods for treating or preventing vascular graft failure in a subject in need of such treatment, the method comprising administering a therapeutically effective amount of a composition comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof, and a pharmaceutically acceptable carrier. The methods also are clinically useful for treating a pre-atherosclerotic intimal hyperplasia condition.

Priority: US20100347495P Applic. Date: 2010-05-24

Inventor: LANDER CYNTHIA [US]; PANITCH ALYSSA [US]; BROPHY COLLEEN [US]; SEAL BRANDON [US]


Publication No.: WO2011150067A1  Published: 01/Dec/2011

Title: TREATMENT OF BLOOD LIPID ABNORMALITIES AND OTHER CONDITIONS

Applicant/Assignee: GLAXOSMITHKLINE LLC

Application No.: US2011/037912   Filing Date: 25/May/2011

Abstract:There is provided a method of treatment of a patient suffering from blood lipid abnormality or abnormality of blood alanine aminotransferase concentration or abnormality of blood uric acid concentration, which comprises the administration of 5-[({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}methyl)oxy]-2-[4-(methylsulfonyl)phenyl]pyridine or a pharmaceutically acceptable salt thereof to a mammal, particularly a human, in need thereof. The method can be used to treat dyslipidemia and may be employed in other blood abnormalities arising in such diseases or conditions as atherosclerotic cardiovascular disease, hepatitis C virus infection, non-alcoholic fatty liver disease, and/or hyperuricemia in patients.

Priority: US20100349268P Applic. Date: 2010-05-28

Inventor: NUNEZ DEREK [US]


Publication No.: WO2011153157A2  Published: 08/Dec/2011

Title: BENZOQUINOLONE INHIBITORS OF VMAT2

Applicant/Assignee: AUSPEX PHARMACEUTICAL, INC

Application No.: US2011/038592   Filing Date: 31/May/2011

Abstract:The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.Formula (I)

Priority: US20100350090P Applic. Date: 2010-06-01

Inventor: GANT THOMAS G [US]; ZHANG CHENGZHI [US]; SHAHBAZ MANOUCHEHR [US]


Publication No.: WO2011153513A2  Published: 08/Dec/2011

Title: NANOEMULSION COMPOSITION CONTAINING VITAMIN K

Applicant/Assignee: LATITUDE PHARMA

Application No.: US2011/039188   Filing Date: 03/Jun/2011

Abstract:In certain embodiments, this invention sets forth compositions, methods, and uses regarding a nanoemulsion composition that comprises a fat-soluble vitamin K and can therapeutically replace Phytonadione Injectable Emulsion, USP.

Priority: US20100350986P Applic. Date: 2010-06-03

Inventor: CHEN ANDREW X [US]


Publication No.: WO2011154755A1  Published: 15/Dec/2011

Title: NANOSTRUCTURED ATORVASTATIN, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS OF THEM, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Applicant/Assignee: NANOFORM CARDIOVASCULAR THERAPEUTICS LTD

Application No.: HU2011/000051   Filing Date: 08/Jun/2011

Abstract:The present invention is directed to nanostructured Atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Atorvastatin, its pharmaceutically acceptable salts and compositions of them according to the invention have an average particle size of less than about 600 nm. The stable amorphous nanostructured particles of the present invention are characterized by increased solubility and bioequivalent biological performance compared to the marketed crystalline drug. Atorvastatin is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms.

Priority: HU20100000299 Applic. Date: 2010-06-08

Inventor: FILIPCSEI GENOVEVA [HU]; OETVOES ZSOLT [HU]; HELTOVICS GABOR [HU]; DARVAS FERENC [HU]


Publication No.: WO2011156711A1  Published: 15/Dec/2011

Title: NANOPARTICLE FILM DELIVERY SYSTEMS

Applicant/Assignee:

Application No.: US2011/039979   Filing Date: 10/Jun/2011

Abstract:A therapeutic or bioeffecting film delivery system which includes nanoparticles having actives bound to or associated with the nanoparticles and which when administered allow the active to perform a therapeutic or bioeffecting function.

Priority: US20100353366P Applic. Date: 2010-06-10

Inventor: SCHOBEL ALEXANDER M [US]; MYERS GARRY L [US]; KENDALL KEITH JOSEPH [US]; RADEMACHER THOMAS [GB]; MOUS JAN [CH]; BARRY JUSTIN N W [ES]; WILLIAMS PHILLIP [GB]; BARRIENTOS AFRICA GARCIA [ES]


Publication No.: WO2011157283A1  Published: 22/Dec/2011

Title: TREATMENT OF COAGULOPATHY WITH HYPERFIBRINOLYSIS

Applicant/Assignee: PAION DEUTSCHLAND GMBH

Application No.: EP2010/007632   Filing Date: 15/Dec/2010

Abstract:The present invention relates to the use of thrombomodulin analogues for the manufacture of a medicament for the treatment of coagulopathy with hyperfibrinolysis, such as haemophilia disorders. These thrombomodulin analogues exhibit at therapeutically effective dosages an antifibrinolytic effect. Novel protein modifications together with methods for their identification are disclosed.

Priority: WO2010EP03541 Applic. Date: 2010-06-14

Inventor: PETERSEN KARL-UWE [DE]; NESHEIM MICHAEL ERNEST [CA]; FOLEY JONATHAN HERBERT [CA]


Publication No.: WO2011157724A1  Published: 22/Dec/2011

Title: S100A4 ANTIBODIES AND THERAPEUTIC USES THEREOF

Applicant/Assignee: LYKERA BIOMED SA

Application No.: EP2011/059868   Filing Date: 14/Jun/2011

Abstract:The disclosure relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof.

Priority: EP20100382170 Applic. Date: 2010-06-14

Inventor: HERNANDEZ MIGUEZ JOSE LUIS [ES]; ADAN PLANA JAUME [ES]; MARTINEZ ESCOLA JOSEP MARIA [ES]; MASA ALVAREZ MARC [ES]; MESSEGUER PEYPOCH RAMON [ES]; MITJANS PRAT FRANCESC [ES]; DAKHEL PLAZA SHEILA [ES]; COLL MANZANO ANTONIO [ES]; HERVAS VILLEGAS ROSA MA [ES]; CALVIS CALPE CARME [ES]; PADILLA GARCIA LAURA [ES]; ROQUE NAVARRO LOURDES TATIANA [ES]; BARBERA FERRANDO LAURA [ES]; RIVAS CANAS MANUEL [ES]; GOMEZ CASAJUS LUIS ANGEL [ES]


Publication No.: WO2011162904A2  Published: 29/Dec/2011

Title: MULTIDOMAIN BIOTAGS FOR CANCER DETECTION, DIAGNOSIS AND THERAPY AND METHODS OF THEIR USE PRIORITY STATEMENT

Applicant/Assignee:

Application No.: US2011/037823   Filing Date: 24/May/2011

Abstract:In one embodiment, a biotag for targeting a cancer biomarker is provided. The biotag may include a cancer biomarker binding domain, an internalization domain, an endosomal escape domain, a lysosomal escape domain, a reporter binding domain, and a reporter, wherein the reporter is a diagnostic agent. In some aspects, the cancer biomarker is ERBB 1 -4, EGFRvlll or Transferrin Receptor (TfR). In other aspects, the binding domain is an scFv, an sdFv, a CDR or an SDR modified CDR. In some aspects, the reporter binding domain is a metal binding domain, which may be chelated to a metal nanoparticle tag. In some aspects, the metal nanoparticle tag is a noble metal, a superparamagnetic metal, a core-shell nanoparticle, or a fluorescent agent. In another embodiment, a targeted contrast composition for use with a diagnostic imaging technique is provided, which includes a contrast agent and a biotag for targeting a cancer biomarker.

Priority: US20100358883P Applic. Date: 2010-06-25; US20100358880P Applic. Date: 2010-06-25; US20100347811P Applic. Date: 2010-05-24; US20100347810P Applic. Date: 2010-05-24; US20100347809P Applic. Date: 2010-05-24

Inventor: MALECKI MAREK [US]; MALECKI RAF [US]


Publication No.: WO2011163473A1  Published: 29/Dec/2011

Title: GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS

Applicant/Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

Application No.: US2011/041623   Filing Date: 23/Jun/2011

Abstract:Provided herein are glucagon analogs comprising a modified amino acid sequence of native human glucagon with (a) a substitution of Ser at position 16 of native glucagon (SEQ ID NO: 1) with an a,a-disubstituted amino acid, optionally alpha, aminoisobutyric acid

a substitution of the Gin at position 3 of native human glucagon (SEQ ID NO: 1) with a glutamine analog

a substitution of Arg at position 17 of native human glucagon (SEQ D NO: 1) with a negative-charged amino acid

optionally, at least one charged amino acid C-terminal to the amino acid at position 27 of the glucagon peptide

and optionally, up to 10 additional amino acid modifications. Related dimers, conjugates, fusion peptides, pharamaceutical compositions, kits, and methods of using the pharmaceutical compositions are also provided herein.

Priority: US20100358710P Applic. Date: 2010-06-25

Inventor: DIMARCHI RICHARD D [US]; DIMARCHI MARIA [US]; CHABENNE JOSEPH [US]


Publication No.: WO2011163533A2  Published: 29/Dec/2011

Title: ONE STEP REMOVAL OF SELECTED MOLECULES FROM BODY FLUID AND TISSUE

Applicant/Assignee: ADVANCED EXTRAVASCULAR SYSTEM, INC

Application No.: US2011/041714   Filing Date: 24/Jun/2011

Abstract:A method for reducing the number of selected antibodies in a subject's blood, the method comprising removing blood from the subject, passing the blood along an enclosed pathway, wherein the pathway comprises one or more semi-permeable hollow fibers with one or more membranes having surfaces positioned substantially perpendicular to the length of the one or more hollow fiber and antigens specific for the antibodies immobilized on the one or more membranes, returning the treated blood to the internal circulation of the subject, wherein the returned treated blood has a reduced number of selected antibodies compared to before treatment.

Priority: US2010-803400 Applic. Date: 2010-06-25

Inventor: BRISTOW DUKE K [US]


Publication No.: WO2011163646A2  Published: 29/Dec/2011

Title: METHODS FOR DETECTION, DIAGNOSIS AND SELECTIVE ERADICATION OF NEOPLASMS AND CIRCULATING TUMOR CELLS USING MULTIDOMAIN BIOTAGS

Applicant/Assignee:

Application No.: US2011/041921   Filing Date: 25/Jun/2011

Abstract:A method for treating cancer in a subject is provided, the method comprising administering to the subject an effective dose of a multidomain biotag that targets one or more cancer cells

and exposing the subject to one or more rounds of radiation. The one or more rounds of radiation kills the one or more cancer cells targeted by the biotag, but, in general, does not kill healthy cells or kills a negligible number of healthy cells. Additionally, a method for treating cancer in a subject is provided, the method comprising administering to the subject an effective dose of a multidomain biotag that targets one or more cancer cells

establishing a vascular access in the subject

connecting the vascular access to an anti-coagulation coated tube to establish an extracorporeal circulation of a bodily fluid

and exposing the extracorporeal circulation to one or more doses of radiation, killing biotag-targeted cancer cells.

Priority: US20100358880P Applic. Date: 2010-06-25; US20100358883P Applic. Date: 2010-06-25

Inventor: MALECKI MAREK [US]; MALECKI RAF [US]

...or search a US patent No (ex:
7666555) or a US patent
application (ex: 2003123456)
or a World (PCT) No (Ex:
2007666555)
Search for anything. Simply
type the words in the box..
World Patents Published in 2010
World Patents Published in 2010
WORLD - PCT PATENT DOCUMENTS IN BLOOD ANTICLOT TECHNOLOGY PUBLISHED FROM IN 2011
This list includes World Patent Documents published by PCT. The list was retrieved by searching the claims section of all patent applications. Salient search terms included drugs,
medications, formulation and devices related to blood anticlotting; blood thinners, anticoagulants, protease enzymes, coumadin and thrombin drugs, thrombin inhibitors, heparin, warfarin
and related technologies. The document search strategy of Formula Scan™ includes proprietary direct and proximity data mining algorithms to retrieve highly relevant documents.